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As the COVID-19 virus continues to rage out of control in the United
States, there are thousands of ongoing clinical trials seeking to develop even
a single effective treatment or vaccine. But the only access to the products
being tested is by enrolling in a Food and Drug Administration (FDA)
supervised clinical trial. And inclusion in a clinical trial has always been by
invitation only. This paper addresses a long-ignored injustice: on the thirtieth
anniversary of the Americans with Disabilities Act (“ADA”) people living
with disabilities have found that they are rarely on the clinical trial invitation
list. This paper will be the first law review article to focus on the widespread
exclusion of people living with disabilities from research studies. Although
the situation has attracted some notice in bioethics, public health, and
disability advocacy communities, there has never been an effort to identify
the entities that fund and conduct research as covered entities subject to the
ADA. This paper will make the case for immediate action by the Justice
Department to ensure that all covered entities are aware of their obligations
under the ADA both to remove the barriers that are either directly or by effect
excluding people living with disabilities and to take proactive steps to
promote their inclusion.
It will do so by first marshalling the evidence of exclusion and its
resulting harm and then analyzing the characteristics of entities conducting
research studies that make them covered entities under the ADA. Moreover,
the Article addresses directly the most likely justifications for excluding people
living with disabilities, which are of the same type routinely rejected by courts.
Adoption of universal design principles in research studies, such as adding
captions to materials necessary for communicating with potential participants,
is only one of many steps that could be implemented immediately.
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INTRODUCTION
As this article is being written, the world faces a global pandemic
caused by the rapid spread of a new virus1 to which no one is yet immune,
from which millions have become infected2 and hundreds of thousands have
already died,3 and for which—during the first year of the pandemic—there
were no known effective vaccines 4 or treatments.5 There is already evidence
that people living with disabilities 6 are not just being disparately impacted by
COVID-19, CTRS. FOR DISEASE CONTROL & PREVENTION, https://www.cdc.gov/corona
virus/2019-nCoV/index.html [https://perma.cc/X5Z7-VM7E] (last visited Feb. 1, 2021).
2
CDC COVID Data Tracker, CTRS. FOR DISEASE CONTROL & PREVENTION, https://www.cdc.
gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html [https://perma.cc/A7TM-P6SG]
(last visited Jan. 25, 2021).
3
To view a more accurate death count attributable to COVID-19 at any point in time, see
Excess Deaths Associated with COVID-19, CTRS. FOR DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm [https://perma.cc/88CX66FG] (last visited Jan. 25, 2021); Daily Updates of Totals by Week and State, CTRS. FOR
DISEASE CONTROL & PREVENTION, https://www.cdc.gov/nchs/nvss/vsrr/covid19/index.htm
[https://perma.cc/N8Z6-RPZT] (last visited Feb. 1, 2021).
4
Coronavirus Disease (COVID-19) Advice for the Public: Mythbusters, WORLD HEALTH
ORG., https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/
myth-busters [https://perma.cc/BSB3-DYSA] (last visited Jan. 25, 2021).
5
See id. (“There is currently no licensed medication to cure COVID-19.”).
6
Language matters. This article will use the words “people living with disabilities” to
describe the human beings who are discriminated against by being excluded from research,
but will reproduce as written descriptions that are part of existing statutes, cases, and other
1
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the virus but are being excluded from ICU care. 7 The only options for people
who seek to avoid infection are to stay at home or take basic public health
hygiene precautions. As the Mayo Clinic describes the situation, “[w]ith the
number of COVID-19 cases and deaths rising with each day, there is perhaps
no more pressing need in medicine than to identify safe and effective
therapies to prevent SARS-CoV-2 infections and to lessen the severity of the
resulting COVID-19 respiratory illness.”8 As one commenter recently noted,
“[e]xperimental treatments are standard of care in the absence of an approved
treatment.”9

documents. It does so based on guidelines issued by The National Center on Disability and
Journalism at Arizona State University, which advocates “people-first language unless
otherwise indicated by the source.” Disability Language Style Guide, NAT’L CTR. ON
DISABILITY AND JOURNALISM, https://ncdj.org/style-guide [https://perma.cc/RV4D-9LLB]
(last visited Feb. 16, 2021). See Labib Rahman, Disability Language Guide, STANFORD
DISABILITY INITIATIVE BOARD (July 2019), https://disability.stanford.edu/sites/g/files/sbiy
bj1401/f/disability-language-guide-stanford_1.pdf [https://perma.cc/6ALY-7E3J] (stating
that “there is not a monolithic language style preference shared across all the people who
have a disability”).
7
Since the pandemic is still ongoing, it is too early to know the scope of actual exclusions
although there have been reports of individual incidents. See Joseph Shapiro, Oregon
Hospitals Didn’t Have Shortages. So Why Were Disabled People Denied Care?, NPR (Dec. 21,
2020, 3:21 PM), https://www.npr.org/2020/12/21/946292119/oregon-hospitals-didnt-haveshortages-so-why-were-disabled-people-denied-care [https://perma.cc/95PK-JVFW] (describing
an incident in Oregon where a disability rights organization intervened on behalf of an
individual with intellectual disability who came to the hospital with COVID-19 and was not
given access to a ventilator despite difficulty with breathing. The patient was transferred to
another hospital where she was put on a ventilator and recovered. An investigation found
that the patient was “being inappropriately influenced about life-sustaining treatment. And
the physician in that case talked about the quote ‘low quality of life’ of a person with a
disability.”). For an interim overview of some of the concerns expressed about the impact of
the pandemic on people living with disabilities, see Elizabeth Pendo, COVID-19 and
Disability-Based Discrimination in Health Care, A.B.A. (May 22, 2020), https://www.
americanbar.org/groups/diversity/disabilityrights/resources/covid19-disability-discrimination/
[https://perma.cc/XHF8-C3XE] (“Governmental and private responses to the COVID-19
pandemic can compound these longstanding health inequalities. In particular, because the
COVID-19 pandemic places tremendous strain on our health care system, states, health care
facilities, and professional organizations are developing triage protocols to determine how to
allocate critical health care resources, especially ventilators, when there is not enough
capacity to treat all patients. Disability advocates and organizations have raised serious
concerns about the impact of triage policies that exclude, disadvantage, or otherwise
discriminate on the basis of disability.”).
8
Mayo Clinic Researchers Double Down on COVID-19, MAYO CLINIC, https://www.mayo.edu/
research/covid-19-research [https://perma.cc/94VH-HL79] (last visited Jan. 23, 2021).
9
Glenn Ellis, COVID-19 Vaccine and Treatment Research, PHILA. TRIB. (July 14, 2020),
https://www.phillytrib.com/news/glenn-ellis-covid-19-vaccine-and-treatment-research/
article_0a81d801-165c-503d-8d77-c5aa2f5c4ec0.html [https://perma.cc/53VU-VSGX].
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There is nothing new about people living with disabilities being even
more underserved during times of emergency.10 Professor Sharona Hoffman,
citing the experiences of people with psychiatric disabilities after severe
hurricanes as reported by the National Council on Disability, warned in 2009
“that during triaging processes, some health care providers may determine
that individuals with disabilities are of a lower priority than others because
treating them is more difficult or complicated.” 11 Health care crises also
intersect with the life experiences of people living with disabilities that can
contribute to bad health outcomes. As Professor Jasmine Harris explains, as
a result of “the persistence of social stigma[],” “[p]eople with disabilities
continue to be un- and underemployed and under-educated on the basis of
false conceptions of their agency and humanity.”12 Therefore, as a
population, people living with disabilities have less disposable income than
the general population of the United States and are less able to bear the costs
of travel to research sites. 13
If this were not enough, the situation today involving a new deadly
virus with no available effective treatment is eerily reminiscent of the
situation which led to the creation of a grassroots movement to gain access
See COVID-19 Poses Unique Challenges for People with Disabilities, HUB (Apr. 23, 2020),
https://hub.jhu.edu/2020/04/23/how-covid-19-affects-people-with-disabilities/ [https://perma.cc/
J9WK-ZFUD] (describing how difficult the pandemic has been for people with disabilities
who may depend on the assistance of others to comply with social distancing rules, for people
with communication deficits to get the information they need when everyone is wearing
personal protective equipment, and for people who rely on state mobility services to take
advantage of drive-up testing sites).
11
Sharona Hoffman, Preparing for Disaster: Protecting the Most Vulnerable in
Emergencies, 42 U.C. DAVIS L. REV. 1491, 1500 (2009) (citing NAT’L COUNCIL
ON DISABILITY, THE NEEDS OF PEOPLE WITH PSYCHIATRIC DISABILITIES DURING AND
AFTER HURRICANES KATRINA AND RITA: POSITION PAPER AND RECOMMENDATIONS 6
(2006), https://ncd.gov/publications/2006/07142006 [https://perma.cc/477C-N8YQ]).
12
Jasmine E. Harris, Processing Disability, 64 AM. U. L. REV. 457, 461 (2015); see also
Disability & Socioeconomic Status, AM. PSYCH. ASS’N, https://www.apa.org/pi/ses/
resources/publications/disability [https://perma.cc/E9ST-QHPT] (last visited Jan. 21, 2021)
(“Results from the American Community Survey . . . reveal significant disparities in the
median incomes for those with and without disabilities. Median earnings for people with no
disability were over $30,469, compared to the $20,250 median income reported for
individuals with a disability.”) (citation omitted); Anthony Hicks, Disabled Americans More
Likely to Be Poor and Ignored, COM. APPEAL (Jan. 4, 2018, 5:20 PM),
https://www.commercialappeal.com/story/opinion/contributors/2018/01/04/disabledamericans-more-likely-poor-and-ignored/1002839001/
[https://perma.cc/A9UT-QR8A]
(describing the broad occurrence of poverty among people with disabilities).
13
Cost of travel is a barrier to many underserved populations. See generally Deborah Watkins
Bruner, Stephanie L. Pugh, Katherine A. Yeager, Jesse Bruner & Walter Curran Jr.,
Cartographic Mapping and Travel Burden to Assess and Develop Strategies to Improve
Minority Access to National Cancer Clinical Trials, 93 INT’L J. RADIATION ONCOLOGY
BIOLOGY PHYSICS 702, 708 (2015) (noting that participation in clinical trials can be
improved by focusing on subjects who have difficult difficulty traveling to drug trial sites).
10
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to clinical trials during the early days of the AIDS epidemic,14 particularly in
light of Dr. Anthony Fauci’s leading role in overseeing drug development in
both outbreaks.15
Because there are no approved treatments, people who contract the
virus must depend on the availability of high intensity hospital care and
access to one of many, by definition, experimental treatments through either
enrolling in a clinical drug trial16 or seeking early access to a drug still under
review.17 No curative drug has yet been proved safe and effective. 18 And we

14

These similarities will be discussed in more detail infra in Section II.B. To learn more about
this grassroots movement, ACT UP, see MATT BRIM, CUNY ACAD. WORKS, STUDY GUIDE FOR
UNITED IN ANGER: A HISTORY OF ACT UP (2012), http://academicworks.cuny.edu/
cgi/viewcontent.cgi?article=1001&context=si_oers [https://perma.cc/MS84-627C]. It is also
important to note that ACT UP’s concern was as much about the FDA’s slowness in encouraging
clinical trials of prospective treatments as it was about exclusions from existing trials.
15
See Dave Davies, Long Before COVID-19, Dr. Anthony Fauci ‘Changed Medicine in
America Forever,’ NPR (Apr. 16, 2020 1:12 PM), https://www.npr.org/sections/health-shots/
2020/04/16/834873162/long-before-covid-19-dr-tony-fauci-changed-medicine-in-americaforever [https://perma.cc/VEN6-EXDB] (“[D]uring the height of the AIDS epidemic, Fauci
worked with activists to amend the way the government handles clinical drug trials,” which
“increased the number of patients who had access to experimental HIV/AIDS treatments[,] .
. . saved countless lives,” and, as Michael Specter puts it, “basically forced people to realize
that you can't run drug trials and decide what to do with patients without ever consulting
patients,” which “changed medicine in America forever.”).
16
This article will use the phrase “clinical drug trial” to mean any study with human
participants conducted with the purpose of getting information about a drug or device. This
is somewhat broader than the way the phrase is used by the Food and Drug Administration,
which limits this phrase to studies conducted by private entities for the purpose of gathering
information to apply for permission to sell the drug or vaccine in the United States. However,
the crisis of the COVID-19 pandemic has blurred the already fuzzy lines between public and
private sponsors of drug trials to the extent that using a variety of words for the concept of a
person in need of medical care seeking access to a drug or device not yet on the market would
be more confusing than helpful. For an overview of how the FDA normally regulates clinical
drug trials of the type being conducted for potential COVID-19 cures, see Joshua D. Wallach,
Joseph S. Ross & Huseyin Naci, The US Food and Drug Administration’s Expedited
Approval Programs: Evidentiary Standards, Regulatory Trade-Offs, and Potential
Improvements, 15 CLINICAL TRIALS 219 (2018).
17
For an example of an “expanded access” program allowing the use of treatments still under
review, see Michael J. Joyner, Expanded Access to Convalescent Plasma for the Treatment
of Patients with COVID-19, CLINICALTRIALS.GOV (Sept. 2, 2020), https://clinicaltrials.gov/
ct2/show/NCT04338360 [https://perma.cc/93SU-XPQ7].
18
See Pat Basu & Maurie Markman, Opinion, COVID-19 Is Forcing Us to Rethink Clinical
Trials for Cancer Treatments, SCI. AM. (July 9, 2020), https://www.scientificamerican.com/
article/covid-19-is-forcing-us-to-rethink-clinical-trials-for-cancer-treatments/ [https://perma.cc/
M4YA-68UD] (discussing existing barriers to participation in clinical trials).
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are already seeing barriers excluding people living with disabilities among the
thousands of clinical trials of COVID-19 treatments.19
It is during this most intense need for scarce health care resources that
the disparities in healthcare outcomes faced by people living with disabilities
is most visibly on display. Commenting on the possibility of having to ration
care during the COVID-19 pandemic, Sam Bagenstos warns that triage
protocols that exclude people living with disabilities are illegal because they
are based on “widespread . . . medical bias against people with disabilities.”20
Oregon has already issued a new law, effective July 7, 2020, that prohibits
hospitals from conditioning treatment on the signing of an advanced directive
authorizing the withdrawal of life sustaining care. 21
While today’s situation involving access to COVID-19 trials provides
an entry point, the exclusion transcends any particular subject area of research
or any specific entity conducting research. This article therefore provides a
framework to look at a very serious form of disability discrimination which
until quite recently was almost invisible: the near total exclusion of people
living with disabilities from research studies. Their exclusion, which mirrors
that of much better known excluded populations such as women, children,
and African Americans, causes significant harm at a population level because
they must live in a world organized around research findings that do not
include them.22

19

Information about clinical trials is posted in a database managed by the Department of
Health and Human Services called ClinicalTrials.gov. It is updated frequently. A recent
example is a study of hydroxychloroquine for “COVID-19 infected patients with early
moderate and severe disease” that excludes participants who are not able “to take oral pills
or . . . use a feeding tube.” LCMC HEALTH, Treatment in Patients with Suspected or Confirmed
COVID-19 with Early Moderate or Severe Disease (RCT), CLINICALTRIALS.GOV (Aug. 24,
2020), https://clinicaltrials.gov/ct2/show/NCT04344444 [https://perma.cc/THD8-ND23].
20
Samuel R. Bagenstos, Who Gets the Ventilator? Disability Discrimination in COVID-19
Medical-Rationing Protocols, 130 YALE L.J.F. 1, 21 (2020); see also Preventing
Discrimination in the Treatment of COVID-19 Patients: The Illegality of Medical Rationing
on the Basis of Disability, DISABILITY RTS. EDU. & DEF. FUND (Mar. 25, 2020),
https://dredf.org/the-illegality-of-medical-rationing-on-the-basis-of-disability [https://perma.cc/
W7LT-F6VG] (warning healthcare providers that they are “subject to the disability
nondiscrimination mandates of the ADA” and should be mindful of their obligations when
making “decisions about who should or should not receive care”). DREDF also warned
“lawmakers and providers of health care . . . of their duty to uphold the civil and human
rights of people with disabilities” by not “tak[ing] ‘rationing’ measures.” Id.
21
OR. REV. STAT. § 127.635.
22
See, e.g., Victoria Shepherd, An Under-Represented and Underserved Population in Trials:
Methodological, Structural, and Systemic Barriers to the Inclusion of Adults Lacking
Capacity To Consent, TRIALS, May 29, 2020, at 2 (“The lack of representation of certain
groups in trial populations brings the external validity (the extent to which the results can be
generalised to other circumstances or populations) of trials into question, which is even more
important when these groups are systematically excluded from those trials.”).
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This article is the first to look at the legal implications of this
widespread exclusion and argue that exclusion from research needs to be
recognized as a serious form of disability discrimination prohibited by the
Americans with Disabilities Act (“ADA”).23 It links exclusion from research
with the disparities in healthcare results long recognized in the AfricanAmerican community and other stigmatized and underserved communities 24
in that both phenomena reflect the discrimination and stigma that people
living with disabilities still face more than thirty years after the passing of the
first federal anti-discrimination statutes. 25
Although as of the writing of this article there has never been a
reported account of a person living with a disability invoking antidiscrimination laws to gain access to a research study, they have a legal right
to do so. That they should be aware of this right is especially important now
at a time of a novel virus when access to research studies is so important.
This article proceeds as follows: Part I describes how the exclusion of
people with disabilities from research was uncovered and what is known
about the situation now; Part II then analyzes how this exclusion causes harm
to people living with disabilities and to the larger population of the United
States as a whole. Part III begins the process of identifying a legal solution
by comparing people living with disabilities’ experience of exclusion with
that of other underrepresented populations whose exclusion has been
addressed by law. In the process, it identifies the key issue that distinguishes
people living with disabilities from other populations in terms of exclusion,
which is the concern over the ability of people whose disabling condition
affects their ability to give informed consent. Part IV provides an analysis of
how the provisions of the Americans with Disabilities Act apply to the
different settings in which research is conducted with consideration of the
differences between research subject to Title II of the ADA and Title III.
Finally, it concludes with an overview of why making research accessible to
people living with disabilities is critical to addressing the health and other
disparities they experience. It also calls upon all involved parties to be
proactive in removing barriers that limit the access of people living with
disabilities to research studies early access to drugs.
See Harris, supra note 12, at 460–61 (“The ADA, now approaching its twenty-fifth
anniversary, sought to address discrimination through greater integration of people with
disabilities into society, in part, by increasing their visibility in public spaces. Congress
identified stigma, ‘prejudice, [and] antiquated attitudes’ as the primary impediments to full
inclusion driving the promulgation of the ADA.”).
24
See Olugbenga Ajilore, 3 Ways to Improve the Outcomes for African Americans in the Rural
South, CTR. FOR AM. PROGRESS (Aug. 6, 2019, 12:01 AM), https://www.americanprogress.
org/issues/economy/reports/2019/08/06/470913/3-ways-improve-outcomes-african-americansrural-south/ [https://perma.cc/3SSQ-JN95] (considering the impact of systemic racism).
25
Harris, supra note 12, at 460–61.
23
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I. EXCLUSION OF PEOPLE WITH DISABILITIES FROM RESEARCH: THE
SCOPE OF THE PROBLEM
A. Who Are People Living With Disabilities?
Most Americans are, have, or will be living with a condition that
impairs our ability to engage in at least some activities essential to our daily
lives.26 The number of people living with a disability at any given time
depends on the definition used by the entity collecting the data. The
Convention on the Rights of Persons with Disabilities defines “Persons with
Disabilities” as “those who have long-term physical, mental, intellectual or
sensory [such as hearing or vision] impairments which in interaction with
various barriers may hinder their full and effective participation in society on
an equal basis with others.”27 The United States Census Bureau reports that
12.7% of the population of the United States (41,089,958 individuals) are
living in their communities with a disability. 28 These percentages go up with
age. The Pew Charitable Trust’s 2015 survey found that “[a]bout half of
Americans ages 75 and older (49.8%) reported living with a disability in
2015, as did about a quarter (25.4%) of those 65 to 74.”29 U.S. law prohibiting
disability-based discrimination takes a functional approach by considering
the effect of a disabling condition while erasing distinctions based on
“gender, race, ethnicity, sexual orientation, or social status.”30

U.S. DEP’T OF HEALTH & HUMAN SERVS., THE SURGEON GENERAL’S CALL TO ACTION TO
IMPROVE THE HEALTH AND WELLNESS OF PERSONS WITH DISABILITIES 1 (2005), https://
www.ncbi.nlm.nih.gov/books/NBK44667/pdf/Bookshelf_NBK44667.pdf [https://perma.cc/P8CA
-KVTW] (explaining that “[m]ost individuals in the United States will experience a disability
of some duration at some point in their lives”).
27
United Nations Convention on the Rights of Persons with Disabilities art. 1, Dec. 13, 2006,
S. TREATY DOC. NO. 112-7, 2515 U.N.T.S. 72 [hereinafter United Nations].
28
2019 American Community Survey 1-Year Estimates Subject Tables: Disability Characteristics,
U.S. CENSUS BUREAU, https://data.census.gov/cedsci/table?q=disability& tid=ACSST1Y2019.
S1810&hidePreview=false [https://perma.cc/763D-3PZ7] (last visited Feb. 2, 2021). The Census
Bureau excludes people who are living in hospitals or other medical settings.
29
Kristen Bialik, 7 Facts About Americans with Disabilities, PEW RSCH. CTR. (July 27,
2017), http://www.pewresearch.org/fact-tank/2017/07/27/7-facts-about-americans-with-dis
abilities/ [https://perma.cc/R849-CSZK].
30
See JAMES I. CHARLTON, NOTHING ABOUT US WITHOUT US: DISABILITY OPPRESSION AND
EMPOWERMENT 157 (1998) (quoting MICHELLE FINE & ADRIENNE ASCH, WOMEN WITH
DISABILITIES: ESSAYS IN PSYCHOLOGY, CULTURE AND POLITICS 3 (1988)) (“To date almost
all research on disabled men and women seems simply to assume the irrelevance of gender,
race, ethnicity, sexual orientation, or social status. Having a disability presumably eclipses
these dimensions of social experience. Even sensitive students of disability . . . have focused
on disability as a unitary concept and have taken it to be not merely the ‘master’ status but
apparently the exclusive status for disabled people.”).
26
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B. What Makes People With Disabilities A Disparately Impacted Population
In Terms Of Health Care Results?
At every stage in maintaining wellness and receiving treatment when
facing illness, people living with disabilities face physical and institutional
barriers to care.31 Their experience echoes the experience of other stigmatized
groups who experience worse health outcomes than could be predicted by
any other variable such as wealth or geographic location. 32 As a result, they
receive less care, have less interaction with medical professionals for
conditions unrelated to their disability, and have far worse health outcomes. 33
This exclusion exists despite clear protections provided by U.S. civil rights
laws prohibiting discrimination in healthcare based on disability. 34
See NAT’L COUNCIL ON DISABILITY, THE CURRENT STATE OF HEALTH CARE FOR PEOPLE WITH
DISABILITIES 23 (2009), https://files.eric.ed.gov/fulltext/ED507726.pdf [https://perma.cc/4U3AUD8D] (discussing gaps in and barriers to care for people living with disabilities); Lenny
Bernstein, People with Autism, Intellectual Disabilities Fight Bias in Transplants, WASH.
POST (Mar. 4, 2017), https://www.washingtonpost.com/national/health-science/people-withautism-intellectual-disabilities-fight-bias-in-transplants/2017/03/04/756ff5b8-feb2-11e6-8f4
1-ea6ed597e4ca_story.html [https://perma.cc/Q2U2-N5SR] (detailing the stories of
individuals denied healthcare procedures because of their disabilities).
32
See Vickie M. Mays, Susan D. Cochran & Namdi W. Barnes, Race, Race-Based
Discrimination, and Health Outcomes Among African Americans, 58 ANN. REV. PSYCH. 201, 204
(2007) (reviewing literature documenting the effect of stigma on the health outcomes of African
Americans, which are worse than those for white Americans, and concluding that “the causal
mechanism linking racial/ethnic minority status and health disadvantage is thought to lie in the
harmful effects of chronic experiences with race-based discrimination, both actual and
perceived.”). For a discussion of how perceptions of stigmatized populations affect health results,
see Valarie K. Blake, Remedying Stigma-Driven Health Disparities in Sexual Minorities, 17
HOUS. J. HEALTH L. & POL’Y 183, 200 (2017) (“[T]here is a correlation—though not necessarily
causation—between high stigma communities and higher mortality for the majority populations,
as well. Data supports increased mortality for all populations in areas that had significant racism,
sexism, and other forms of discrimination.”).
33
This exclusion extends to discrimination in times of public health emergencies. See Wendy
F. Hensel & Leslie E. Wolf, Playing God: The Legality of Plans Denying Scarce Resources
to People with Disabilities in Public Health Emergencies, 63 FLA. L. REV. 719, 723 (2011)
(noting that guidelines for providing resources during a potential swine flu epidemic
explicitly excluded people “from critical care either because they will need resources for a
prolonged period of use, are deemed to have a poor quality of life post-treatment, or
otherwise have a limited long-term prognosis as a result of their disabilities”).
34
See Debra T. Berube & Gary C. Norman, Improving Healthcare Access for People with
Disabilities: A Call to Maryland’s Leaders, 45 MD. B.J. 12, 14 (2012) (citing Julia Rothstein
& Laura F. Rothstein, Access to Healthcare: Statutory Overview—Reasonable
Accommodation, in DISABILITIES & THE LAW § 10:3 (4th ed. 2009)) (“If an individual meets
the definition of disability, then affirmative requirements under the Americans with
Disabilities Act, and its predecessor, the Rehabilitation Act of 1973, provide that individual
with rights to accommodation and non-discrimination.”); Elizabeth Pendo, Reducing
Disparities Through Health Care Reform: Disability and Accessible Medical Equipment, 4
31
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The lack of participation of people with intellectual disabilities in
research projects that affect them has long been a concern in the U.K. and
Europe, leading to substantial efforts to address the issues raised by the
challenges of obtaining informed consent.35 But there has also been more
general appreciation that exclusion has extended to people living with
disabilities who were fully competent to consent, but who were nevertheless
almost completely absent from research on any topic. In 2012, Dr. Shirley M.
Moore, who with Dr. Ann S. Williams has made specific recommendations for
designing research to be more inclusive for all participants and has become a
leading voice in developing universal design for research, published an article
noting the absence of people with disabilities in diabetes research.36
The first major article to consider exclusion came from the field of
public health.37 Drs. Dianne Rios and Mark Harniss at the Department of
Rehabilitation Medicine at the University of Washington in Seattle described
their absence as, first, “a civil rights issue,” and second, a breach of “scientific
integrity.”38 While evaluating the scope, scale, and significance of the
exclusion of people with living disabilities is an ongoing process, there is
UTAH L. REV. 1057, 1065 (2010) (“Although the ADA establishes the necessary foundation
for ensuring equal and accessible care for people with disabilities, people with disabilities
continue to experience significant barriers to care, including basic preventive health
services.”); see also Disability & Socioeconomic Status, supra note 12 (citing Mari-Lynn
Drainoni, Elizabeth Lee-Hood, Carol Tobias, Sara S. Bachman, Jennifer Andrew & Lisa
Maisels, Cross-Disability Experiences of Barriers to Health-Care Access: Consumer
Perspectives, 17 J. DISABILITY POL’Y STUD. 101, 102 (2006)) (“Research on disability and
health care suggests that individuals with a disability experience increased barriers to
obtaining health care as a result of accessibility concerns, such as transportation, problems
with communication and insurance.”).
35
Victoria Shepherd, Fiona Wood, Richard Griffith, Mark Sheehan & Kerenza Hood,
Protection by Exclusion? The (Lack of) Inclusion of Adults Who Lack Capacity to Consent
to Research in Clinical Trials in the UK, TRIALS, Aug. 5, 2019, at 2–3 (2019) [hereinafter
Shepherd et al., Protection by Exclusion]. See also Victoria Shepherd, Fiona Wood, Richard
Griffith, Mark Sheehan & Kerenza Hood, Research Involving Adults Lacking Capacity to
Consent: A Content Analysis of Participant Information Sheets for Consultees and Legal
Representatives in England and Wales, 20 TRIALS 1, 8–9 (2019) [hereinafter Shepherd et al.,
Lacking Capacity] (analyzing the written information given to proxy decision makers for
permission to participate in research trials).
36
Shirley M. Moore, Scientific Reasons for Including Persons with Disabilities in Clinical
and Translational Diabetes Research, 6 J. DIABETES SCI. & TECH. 236 (2012); see also Ann
S. Williams & Shirley M. Moore, Universal Design of Research: Inclusion of Persons with
Disabilities in Mainstream Biomedical Studies, 3 SCI. TRANSLATIONAL MED. 1, 3 (2011)
(“We propose [Universal Design of Research]—defined as the design of research so that all
people can be included as potential participants, to the greatest extent possible, without the
need for adaptation or specialized design—as a new model for research.”).
37
Dianne Rios, Susan Magasi, Catherine Novak & Mark Harniss, Conducting Accessible
Research: Including People with Disabilities in Public Health, Epidemiological, and
Outcomes Studies, 106 AM. J. PUB. HEALTH 2137, 2137–38 (2016).
38
Id. at 2143.
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enough evidence to consider the meaning of this exclusion, the reasons
behind it, and the path forward using legal tools to begin addressing a public
health calamity that will require considerable change in how research is
funded and conducted in the United States. 39
Not surprisingly, the health outcome disparities are even greater for
people with disabilities who also belong to other groups that experience
disparately poor health outcomes such as African Americans,
Hispanics/Latinos, American Indians, low socioeconomic status populations,
rural populations, and members of the LGBTQ community. 40 The harm is
intensified by the fact that members of this community are themselves more
likely to also be living with mobility and other forms of disability that
negatively impact healthcare outcomes. 41
C. Documenting Exclusion from Research
As with so many things related to disability-based discrimination, the
challenge faced in documenting exclusion from research is that it has for so
long been invisible to researchers—although not to the people living with
disabilities themselves. 42 Responding to the FDA’s 2013 call for comments
See Director’s Message, Sexual and Gender Minorities Formally Designated as a Health
Disparity Population for Research Purposes, NAT’L INST. ON MINORITY HEALTH & HEALTH
DISPARITIES (Oct. 6, 2016), https://www.nimhd.nih.gov/about/directors-corner/messages/
message_10-06-16.html [https://perma.cc/NCZ2-VTUD] (“Mounting evidence indicates
that SGM populations have less access to health care and higher burdens of certain diseases,
such as depression, cancer, and HIV/AIDS. But the extent and causes of health disparities
are not fully understood, and research on how to close these gaps is lacking.”).
40
See generally 1 NAT’L INSTS. OF HEALTH, U.S. DEP’T OF HEALTH & HUMAN SERVS., NIH
HEALTH DISPARITIES STRATEGIC PLAN: FISCAL YEARS 2004–2008 (2004), https://www.
nimhd.nih.gov/docs/2004_2008_strategic_plan_vol1.pdf [https://perma.cc/4ZSM-YQLN]
(discussing healthcare disparities in underserved populations); OFF. OF MINORITY HEALTH,
U.S. DEP’T OF HEALTH & HUMAN SERVS., COMPENDIUM OF FEDERAL DATASETS
ADDRESSING HEALTH DISPARITIES (2019), https://www.minorityhealth.hhs.gov/assets/pdf/
2019%20IHEC%20Data%20Compendium_FullDocument_RegularFormat%20-%202-6-20508-2.pdf [https://perma.cc/8RBZ-2QVE] (compiling federal datasets showing disparities in
healthcare).
41
SILVIA YEE, DISABILITY RTS. EDUC. & DEF. FUND, HEALTH AND HEALTH CARE
DISPARITIES AMONG PEOPLE WITH DISABILITIES (2011) (citing HEALTH & HUM. SERVS.
ADVISORY COMM. ON MINORITY HEALTH, ASSURING HEALTH EQUITY FOR MINORITY
PERSONS WITH DISABILITIES: A STATEMENT OF PRINCIPLES AND RECOMMENDATIONS 11
(2011)), https:// dredf.org/healthcare/Health-and-Health-Care-Disparities-Among-Peoplewith-Disabilities. pdf [https://perma.cc/VPP9-XSP6] (“Aside from the public health issues
that most racial/ ethnic minorities face, minorities with disabilities experience additional
disparities in health, prejudice, discrimination, economic barriers, and difficulties accessing
care as a result of their disability—in effect, they face a “double burden.”).
42
See, e.g., Michelle Hardy, When People Talk About Me as If I’m Not There Because I Have
39
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on a plan to increase information about “how new drugs and devices work in
people with disabilities,” the Disability Rights Education & Defense Fund
(DREDF) wrote that it was “difficult to assess or critique” the plan because
“information concerning disability is routinely excluded from clinical
research in general.”43 Therefore, “[s]cientific evidence is lacking about
effective treatments for people with disabilities . . . because they are routinely
excluded from clinical trials.”44 If you are looking for it, information about
the exclusion of people living with specific kinds of disabilities is scattered
throughout the scientific, medical, and social science literature. 45 But until
very recently, evidence of exclusion of people with disabilities came to light
only when consumers of research, such as physicians, psychologists, and
teachers, who looking for evidence-based interventions were surprised
enough to find nothing and wrote up that result.46
For example, Dr. Maurice Feldman took a random sample of research
studies from “two well-respected, high profile” child development journals
from 1996 to 2010 looking for the inclusion of children with disabilities as
subjects.47 He reported that he and his team “found that most studies probably
did not include children with disabilities” even though they “represent

a Disability, MIGHTY (Aug. 17, 2016), https://themighty.com/2016/08/being-treated-asinvisible-because-i-have-a-disability/ [https://perma.cc/9Q79-A4NE] (recounting an incident
in an airport when a passenger seeking to cut ahead of the author at the security line asked a
stranger standing nearby if it was okay to cut in front of “her”). The author of this article
explained that people with disabilities being treated as invisible
actually happens quite often to people with visible disabilities. I don’t
know if it’s because people are scared to talk to us because we’re a bit
different, or if they assume we might not be able to comprehend situations
or speak to people. Or maybe it’s a completely different reason I haven’t
yet cracked, but it is always unsettling to realize that people talk about you
when you are right there, without seeming to acknowledge your presence.
Id.
43
Disability Rights Educ. & Def. Fund, Comment Letter on Food and Drug Administration’s
Report: Collection, Analysis, and Availability of Demographic Subgroup Data for FDAApproved Medical Products (Nov. 20, 2013) https://dredf.org/wp-content/uploads/2013/
11/FDA-demographic-data-disability-response-11-20-13-Final.pdf [https://perma.cc/VP P9XSP6] [hereinafter DREDF Comment Letter].
44
Id.
45
For an example of studies looking at the exclusion of people with disabilities from research
on specific topics, see Monika Mitra, Susan L. Parish, Karen M. Clements, Xiaohui Cui &
Hafsatou Diop, Pregnancy Outcomes Among Women with Intellectual and Developmental
Disabilities, 48 AM. J. PREVENTIVE MED. 300 (2015).
46
See Maurice A. Feldman, Susan M. Battin, Olivia A. Shaw & Ruth Luckasson, Inclusion
of Children with Disabilities in Mainstream Child Development Research, 28 DISABILITY &
SOC’Y 997, 998 (2013) (“The precise prevalence of children with disabilities in current
research is unknown, but is considered under-representative.”).
47
Id. at 1000.
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approximately 15% of children.”48 In another study, a Canadian research
team sought information about pregnancy outcomes among women with
intellectual and developmental disabilities. After coming up dry, they dug
deeper and found that “[t]here is no current, valid estimate of the yearly
fertility rate in women with [Intellectual and Developmental Disabilities].” 49
As Dr. Maurice Feldman explains, because “[t]he application of child
development research has led to innovative and effective school, community
and health services, and impacted government policies and funding . . . .
[s]ystematic exclusion of children with disabilities from research . . . may
limit beneficence to them.”50
Concerned about the lack of information about how to develop health
promotion programs for people with disabilities, a team led by Dr. James
Rimmer found that “[t]he vast majority of health promotion research targets
populations who do not have a disability.”51
Now that exclusion of people with disabilities is part of the larger
conversation and more researchers are looking for it, evidence of exclusion
is increasing. A newsletter describing new brain imaging studies noted that
“even though nonverbal or minimally verbal people who have autism
spectrum disorder (ASD) make up between 25 and 30 percent of the total
autistic population, almost no studies have been done focusing on this group
and their particular needs.”52 Similarly, researchers looking for evidencebased research on the effectiveness of different kinds of therapies for anxiety
Id. at 1004. The study found an overall exclusion rate of 89.9%. Id. at 1003.
See Hilary K. Brown, Yona Lunsky, Andrew S. Wilton, Virginie Cobigo & Simone N.
Vigod, Pregnancy in Women with Intellectual and Developmental Disabilities, 38 J.
OBSTETRICS & GYNAECOLOGY CAN. 9, 10, 13 (2016) (finding as a preliminary matter that
“[t]here is no current, valid estimate of the yearly fertility rate in women with IDD” and that,
based on research they conducted, women with intellectual disabilities used medication at
high rates during pregnancy and were more likely to be young, live in poverty, and suffer
from epilepsy, obesity, and mental health problems).
50
Feldman et al., supra note 46, at 998.
51
James H. Rimmer, Kerri A. Vanderbom, Linda G. Bandini, Charles E. Drum, Karen
Luken, Yolanda Suarez-Balcazar & Ian D. Graham, GRAIDs: A Framework for Closing the
Gap in the Availability of Health Promotion Programs and Interventions for People with
Disabilities IMPLEMENTATION SCI., Aug. 14, 2014, at 1, 2. This study proposes new research
designs in order to increase the number of people with disabilities in programs and
interventions as well as research. Id. at 6–7.
52
Brain Imaging Reveals Mechanisms Underlying Auditory Processing in Nonverbal Children
with Autism, NEWS MED. LIFE SCI. (Sept. 18, 2019), https://www.news-medical.net/news/
20190918/Brain-imaging-reveals-mechanisms-underlying-auditory-processing-in-nonverbalchildren-with-autism.aspx [https://perma.cc/CFQ4-BV7Q]; see also Timothy P.L. Roberts,
Junko Matsuzaki, Lisa Blaskey, Luke Bloy, J. Christopher Edgar, Mina Kim, Matthew Ku,
Emily S. Kuschner & David Embick, Delayed M50/M100 Evoked Response Component
Latency in Minimally Verbal/Nonverbal Children Who Have Autism Spectrum Disorder,
MOLECULAR AUTISM, Aug. 15, 2019, at 1, 2 (discussing the frequent exclusion of nonverbal
and minimally verbal people who have ASD from brain imaging research).
48
49
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and depression for people with disabilities reviewed 18,949 papers but found
“only six [randomized control trials] on the management of mental ill health
of any kind for people with mild intellectual disabilities, and all of these were
small, feasibility or pilot studies.”53 They concluded that “randomised
controlled trials of interventions to manage mental ill health in adults with
intellectual disabilities need to be a research priority.”54
Despite the strong calls by Dr. Rios and her team for “[f]ederal
funding agencies” to “emphasize the importance of inclusion of people with
disabilities”55 it took the need to diversify research populations in order to
advance the developing field of personal or precision medicine.
D. The Role of Precision Medicine in Encouraging Diverse Participation in
Research
The growing importance of using genetic information to tailor
medical treatment has been a driving force in calling attention to the
exclusion of entire populations from participation in research and has led to
today’s strong interest in seeking out a more diverse research population that
includes people living with disabilities.56 In his January 20, 2015 State of the
Union Address, President Obama announced his intention to launch a
Precision Medicine Initiative to use advances in genetics to “bring us closer
to curing diseases like cancer and diabetes.”57 This initiative was the product
of rapid advances in science following the launch of the Human Genome
Project (HGP) and its achievement of mapping the human genome. 58 In
particular, technological advances that made it possible to quickly and
Martin Osugo & Sally-Ann Cooper, Interventions for Adults with Mild Intellectual
Disabilities and Mental Ill-Health: A Systematic Review, 60 J. INTELL. DISABILITY RSCH.
615, 619 (2016).
54
Id. at 620.
55
Rios et al., supra note 37, at 2143.
56
See generally Maya Sabatello, Lou Ann Blake, Audrey Chao, Arielle Silverman, Ronit
Ovadia Mazzoni, Yuan Zhang, Ying Chen & Paul S. Appelbaum, Including the Blind
Community in Precision Medicine Research: Findings from a National Survey and
Recommendations, 21 GENETICS MED. 2631 (2019) (discussing the obstacles to inclusion of
blind people in research).
57
Address Before a Joint Session of the Congress on the State of the Union, 2015 DAILY
COMP. PRES. DOC. 1 (Jan. 20, 2015).
58
For a historical overview of the development of the Human Genome Project, the
significance of its achievement in mapping the human genome, and the resulting creation of
the field of precision medicine see Leroy Hood & Lee Rowen, The Human Genome Project:
Big Science Transforms Biology and Medicine, GENOME MED., Sept. 13, 2013, at 1. See also
Jon Heggie, Genomics: A Revolution in Health Care?, NAT’L GEOGRAPHIC (Feb. 20, 2019),
https://www.nationalgeographic.com/science/2019/02/partner-content-genomics-health-care
[https://perma.cc/35WS-2EQW] (exploring the linkages between human genome research
and pharmacological innovation).
53
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inexpensively sequence individual genomes supported the development of
algorithms that could take the data generated and identify the relationships
between specific groupings of genes, markers, and responses to
medications.59 While physicians have long observed that men and women60
or people from different regions 61 have very different reactions to the same
medications, without the ability to draw comparisons on the genetic level, it
was difficult to translate these observations into actionable treatment. 62 But
it was not until the development of what is now called pharmacogenetics that
it became possible to select the most effective medical treatments for
individuals who were members of a population sharing specific genetic
markers.63 As understanding of the role that genetics plays in both the
likelihood of an individual having a disease or condition64 and an individual’s
responses to medical treatment65 grows, the call for more diverse research
populations has become even more urgent. 66
For further discussion on advances in precision medicine, see The Promise of Precision
Medicine, NAT’L INSTS. HEALTH, https://www.nih.gov/about-nih/what-we-do/nih-turningdiscovery-into-health/promise-precision-medicine [https://perma.cc/V23G-P7TN] (last visited
Feb. 12, 2020).
60
Heather P. Whitley, Sex-Based Differences in Drug Activity, 11 AM. FAM. PHYSICIAN 1254,
1254 (2009) (“Sex-related differences . . . have important implications for drug activity . . . .”)
61
Kunihoto Asano, Yoshiaki Uyama & Masahiro Tohkin, Factors Affecting Drug-Development
Strategies in Asian Global Clinical Trials for Drug Approval in Japan, 11 CLINICAL &
TRANSLATIONAL SCI. 182, 187–88 (assessing the impact of both genetic and cultural “ethnic
differences” between Asian and Caucasian populations on Asian clinical drug trials).
62
See CTRS. FOR DISEASE CONTROL & PREVENTION, Perspectives in Disease Prevention and
Health Promotion Report of the Secretary’s Task Force on Black and Minority Health, 35
MORBIDITY & MORTALITY WKLY. REP. 109 (1986), https://www.cdc.gov/mmwr/preview/
mmwrhtml/00000688.htm [https://perma.cc/75CH-T725] (reporting on the Task Force’s
progress since its establishment in 1984 “in response to the national paradox of steady
improvement in overall health, with substantial inequities in the health of U.S. minorities”).
63
See Heggie, supra note 58 (detailing how pharmacogenomics has transformed the
traditionally generalist approach to drug development).
64
The work of identifying genetic links to disease is ongoing. See, e.g., Nick Shrine et al.,
Moderate-to-Severe Asthma in Individuals of European Ancestry: A Genome-Wide Association
Study, 7 LANCET RESPIRATORY MED. 20, 29–32 (2019) (finding three new genetic asthma
signals in the “largest genetic-association study of moderate-to-severe asthma to date”).
65
Jaime Crespo, A Genetic Cause for Iron Deficiency, HARV. GAZETTE (Apr. 9, 2008),
https://news.harvard.edu/gazette/story/2008/04/a-genetic-cause-for-iron-deficiency
[https://perma.cc/3MHH-QDMP] (describing how differences in individuals’ blood-iron
levels affect physiological functioning of people with different genetic material); Maulana
Bachtiar & Caroline G.L. Lee, Genetics of Population Differences in Drug Response, 1
CURRENT GENETIC MED. REPS. 162, 163 (2013) (“5-Fluorouracil, a commonly used cancer
chemotherapeutic drug, has been frequently reported to exhibit differences in drug response
among different populations.”).
66
Katherine J. Wu, Lack of Diversity in Genetic Research Could Be Costing Us Our Health,
PBS: NOVA (Mar. 21, 2019), https://www.pbs.org/wgbh/nova/article/lack-diversity-genetic59
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When it became increasingly apparent that there were very few “one
on one” correlations between the presence of a particular gene and the
response to a medication, the biomedical research community’s need for a
much more diverse study population took on a greater urgency. 67
Housed at NIH, the genome sequencing team came together quickly.
By November 2015, it published a report outlining a plan for developing “a
large research cohort of one million or more Americans.”68 This large a group
was needed, the task force explained, because past practices of “[r]igorous
evaluation of the safety and efficacy of new preventive and therapeutic
strategies” were “based on the expected response of a ‘typical’ patient.” 69
With a growing understanding of genetics, however, “it is clear that
individual patients can have markedly variable responses to therapy, ranging
from highly efficacious outcome, to no effect, to deleterious outcome.” 70
Soon afterwards, the Working Group realized that the issue wasn’t just
recruiting a larger number of research subjects, but a more diverse one. As a
result, they began a process of building “cultural competence” into the
recruiting process in “recognition that research to improve health outcomes
requires culturally sensitive research designs and collaboration with
racial/ethnic communities.”71 It was in the development of this process, that
research-could-be-costing-us-our-health/ [https://perma.cc/S7K3-C5VL] (“‘Diversity issues
aren’t just moral, but also scientific,’ says Alicia Martin, a geneticist at the Broad Institute of
MIT and Harvard. ‘There’s a staggering disparity that we haven’t grappled with that’s going
to affect clinical tests or other parts of precision medicine.’”).
67
See, e.g., Raj Kurupati, Andrew Kossenkov, Larissa Haut, Senthil Kannan, Zhiquan Xiang,
Yan Li, Susan Doyle, Qin Liu, Kenneth Schmader, Louise Showe & Hildegund Ertl, RaceRelated Differences in Antibody Responses to the Inactivated Influenza Vaccine Are Linked
to Distinct Pre-Vaccination Gene Expression Profiles in Blood, 7 ONCOTARGET 62898,
62905 (2016) (confirming previous studies’ findings that “ethnicity can influence immune
responses to vaccination”).
68
PRECISION MED. INITIATIVE WORKING GRP., NAT’L INSTS. OF HEALTH, THE PRECISION
MEDICINE INITIATIVE COHORT PROGRAM—BUILDING A RESEARCH FOUNDATION FOR 21ST
CENTURY MEDICINE 1 (2015), https://acd.od.nih.gov/documents/reports/DRAFT-PMI-WGReport-9-11-2015-508.pdf [https://perma.cc/N429-UECT].
69
Id. at 6.
70
Id. (“The roots of this variability likely include unrecognized differences in disease
pathophysiology, environmental exposures, social and behavioral factors, and genetic factors.”);
see also Chanita Hughes Halbert, Jasmine McDonald, Susan Vadaparampil, LaShanta Rice &
Melanie Jefferson, Conducting Precision Medicine Research with African Americans, PLOS
ONE, July 21, 2016, at 2 (“Research is now being conducted to identify and understand barriers
and facilitators to African American participation in genomics research . . . .”).
71
Maya Sabatello, Cultivating Inclusivity in Precision Medicine Research: Disability,
Diversity, and Cultural Competence, 10 J. COMMUNITY GENETICS 363, 363–64 (2019)
(“Unlike previous NIH guidelines that only urged researchers to develop appropriate and
culturally sensitive outreach programs, the All of Us Research Program has explicitly
recognized that enrollment and retention of participants entails respectful and culturally
appropriate engagement with them.” (citation omitted)).
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the exclusion of people with disabilities identified by Dr. Rios and her team
caught the attention of researchers developing outreach programs for
underserved populations.72 After decades of scarce or any notice, article after
article was published all telling the same story: that people living with
disabilities were a larger portion of the U.S. population than the previously
identified under-researched groups and that they had never been the subject
of “comprehensive” genetic research. 73
E. Recognition of Exclusion by Private Funders
Another consequence of the exclusion of people living with
disabilities from research is a pervasive lack of information about their needs
as a population apart from direct disability services. 74 In a 2019 open letter to
all private funders, the leaders of the Robert Wood Johnson and Ford
Foundations announced the formation of the “Presidents’ Council on
Disability Inclusion in Philanthropy” to address, collectively, the absence of
programming targeting the needs of people with disabilities. 75 At the same
time, nonprofits are realizing that not only are they violating their moral
principles in excluding people with disabilities, they are also violating the
law. For example, the Chicago Community Trust has issued a 123-page ADA
Compliance Guide for Nonprofits which begins with the exhortation that
“[a]ll nonprofits should review and evaluate their obligations and renew their
See id. at 365 (citing Rios et al., supra note 37) (“Comprehensive data about participation
of people with disabilities in PMR are not available. However, there are reasons to believe
that, without appropriate strategies in place, persons with disabilities will not be well
represented in PMR (similar to most mainstream health research).”).
73
See generally id.; Sabatello et al., supra note 56.
74
See Sabatello, supra note 71, at 367 (“Insufficient knowledge about how to design PM
studies that are accessible to people with a range of abilities (‘universal design’) and that
offer accommodations may also lead to incorrect presumptions . . . .”); Darren Walker,
Ignorance is the Enemy Within: On the Power of Our Privilege, and the Privilege of Our
Power, FORD FOUND. (Sept. 12, 2016), https://www.fordfoundation.org/just-matters/equalschange-blog/posts/ignorance-is-the-enemy-within-on-the-power-of-our-privilege-and-theprivilege-of-our-power/ [https://perma.cc/3CQS-2H2D] (describing how, as President of the
Ford Foundation, Darren Walker did not realize that his initiative to “disrupt[]” “entrenched
inequality of all kinds” failed to mention “a huge community: the more than one billion
people around the world who live with one form of disability or another” and who “face
harsh inequalities” that regularly intersect[] with other forms of inequality we already
address in our work”).
75
Rich Besser & Darren Walker, Real Equity Means Including People with Disabilities in
Philanthropy, CHRON. PHILANTHROPY (Apr. 2, 2019), https://www.philanthropy.com/article/
No-Equity-Without-Everyone-/245991 [https://perma.cc/55ZM-Q7V6] (noting recent
criticism and stating that for “[t]oo long, philanthropy has operated under the premise that
‘disability is a worthy cause, but it isn’t ours.’ But relegating disability-related issues to a
niche grant-making area or, worse, ignoring people with disabilities completely is no longer
acceptable in philanthropy.”).
72
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efforts to offer full and equal access to people with disabilities in light of the
new requirements.”76
F. Finding Evidence of Harm from Exclusion from the Experience of Other
Excluded Populations
Unfortunately, the exclusion of an entire population from
participation in research is an all too familiar story in the United States.
There is extensive evidence of the exclusion of and resulting harm to other
populations, such as African-Americans, 77 the elderly,78 pregnant women,79

Irene Bowen, CHIC. CMTY TR., RENEWING THE COMMITMENT: AN ADA COMPLIANCE
GUIDE FOR NONPROFITS 1 (2015), http://www.cct.org/wp-content/uploads/2015/08/2015
ADAComplianceGuide.pdf [https://perma.cc/UX9H-M9DE].
77
See generally Ruqaiijah Yearby, Exploitation in Medical Research: The Enduring Legacy
of the Tuskegee Syphilis Study, 67 CASE W. RSRV. L. REV. 1171 (2017) (discussing the
Tuskegee Syphilis Study); Barbara A. Noah, The Participation of Underrepresented
Minorities in Clinical Research, 29 AM. J.L. & MED. 221 (2003) (discussing the exclusion
of racial and ethnic minorities from medical research studies); Heather R. Romero, Kathleen
A. Welsh-Bohmer, Lisa P. Gwyther, Henry L. Edmonds, Brenda L. Plassman, Cassandra M.
Germain, Michelle McCart, Kathleen M. Hayden, Carl Pieper & Allen D. Roses, Community
Engagement in Diverse Populations for Alzheimer’s Disease Prevention Trials, 28
ALZHEIMER DISEASE & ASSOCIATED DISORDERS 269, 270 (2014) (discussing the challenges
of recruiting healthy volunteers for Alzheimer’s studies, researchers at Duke noted that “[i]t
is well known that clinical trials for AD do not typically include large numbers of AfricanAmericans (AAs) for a variety of complex historical and societal reasons.”).
78
See Vivek H. Murthy, Harlan M. Krumholz & Cary P. Gross, Participation in Cancer
Clinical Trials: Race-, Sex-, and Age-Based Disparities, 291 JAMA 2720, 2721 (2004)
(“Although elderly patients represent approximately two thirds of cancer patients, they
account for only 25% to 30% of clinical trial participants.”).
79
See Alison Kodjak, Research Gaps Leave Doctors Guessing About Treatments for
Pregnant Women, NPR: SHOTS (Dec. 10, 2018, 3:26 PM), https://www.npr.org/sections/
health-shots/2018/12/10/673897043/research-gaps-leave-doctors-guessing-about-treatmentsfor-pregnant-women [https://perma.cc/24P5-V7MD] (quoting Jacqueline Wolf, describing
the irony of excluding pregnant women from clinical trials: “Because researchers are hardly
ever permitted to conduct trials on pregnant women, we end up experimenting on pregnant
women all the time, because we can't accumulate a solid fund of evidence . . . . we just stick
with the old standards, or we introduce new things without doing trials on them.”). See
generally Barbara A. Noah, The Inclusion of Pregnant Women in Clinical Research, 7 ST.
LOUIS U. J. HEALTH L. & POL'Y 353 (2014) (discussing the need for drug companies to
include pregnant patients in clinical research trials). Unfortunately, this same exclusion of
pregnant women from research trials has persisted in the testing of new COVID-19 vaccines.
See Paul T. Heath, Kirsty Le Doare & Asma Khalil, Inclusion of Pregnant Women in COVID19 Vaccine Development, 20 LANCET 1007, 1007 (Aug. 11, 2020), https://www.thelancet.com/
journals/laninf/article/PIIS1473-3099(20)30638-1 [https://perma.cc/T22R-BCZ5] (“A particular
consideration is that for many of the vaccine candidates and platforms being actively
considered . . . no trials have been done in pregnant women.”)
76
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children,80 Hispanics,81 women as a population, 82 and incarcerated
individuals.83 One of the first substantial public discussions of the harm of
excluding populations came from Professor Rebecca Dresser’s 1992 article
criticizing the practice of limiting medical research subjects to young white
men and noting that the practice “‘resulted in significant gaps in [our]
knowledge’ of diseases that affect both men and women.” 84

For an overview of both the historic exclusion of children from clinical drug trials and the FDA
and Congress’ efforts to increase their participation, see Holly Fernandez Lynch, Give Them What
They Want?: The Permissibility of Pediatric Placebo-Controlled Trials Under the Best
Pharmaceuticals for Children Act, 16 ANNALS HEALTH L. 79 (2007). This exclusion of children
from clinical trials persists in the initial trials of vaccines to prevent COVID-19. See Denise Grady,
Moderna Plans to Begin Testing Its Coronavirus Vaccine in Children, N.Y. TIMES (Feb. 12, 2021),
https://www.nytimes.com/2020/12/02/health/Covid-Moderna-vaccine-children.html
[https://perma.cc/Y88X-LL7J] (noting that, at least as of December 2020, Moderna’s vaccine had
not yet been studied in children); Jared S. Hopkins, Covid-19 Vaccine Makers Turn Toward
Testing Children, WALL STREET J. (Dec. 11, 2020, 7:00 am), https://www.wsj.com/articles/covid19-vaccine-makers-turn-toward-testing-children-11607 688001 [https://perma.cc/M2GS-SU9E]
(mentioning the “omission of children in U.S. vaccine trials”).
81
See Paula Andalo, Latinos Left Out of Clinical Trials . . . and Possible Cures, USA TODAY
(July 24, 2017, 3:16 PM), https://www.usatoday.com/story/news/2017/07/24/kaiser-latinosleft-out-clinical-trials-and-possible-cures/103956714/ [https://perma.cc/L8MG-4TEG] (noting
that Hispanics are often underrepresented in clinical trials).
82
See, e.g., Nathaniel M. Robbins & James L. Bernat, Minority Representation in Migraine
Treatment Trials, 57 HEADACHE 525, 530 (2017) (“Migraine clinical trials uniformly report
the proportion of women in the trial, but only two-thirds report the racial composition of the
study sample. No trials analyze efﬁcacy or safety results by race or sex.”); John J. Whyte,
FDA Drug Trials Snapshots and Diversity When Testing New Drugs, CASE COMPREHENSIVE
CANCER CTR. (May 8, 2017), https://case.edu/cancer/about-us/news/fda-drug-trials-snap
shots-and-diversity-when-testing-new-drugs [https://perma.cc/XFQ2-7EQL] (“For instance,
women are often prescribed only half the dose that men take of the sleep medication, Ambien
(zolpidem). Race and ethnicity also make a difference. One type of drug commonly used to
treat high blood pressure, angiotensin-converting enzyme (ACE) inhibitors, has been shown
to be less effective in African American patients than in white patients.”).
83
See generally Allen M. Hornblum, ACRES OF SKIN: HUMAN EXPERIMENTS AT
HOLMESBURG PRISON (1998) (recounting abuses suffered at a specific prison); Sharona
Hoffman, Beneficial and Unusual Punishment: An Argument in Support of Prisoner
Participation in Clinical Trials, 33 IND. L. REV. 475 (2000) (recounting the abuse of
prisoners forced to participate in biomedical experimentation, but arguing that prisoners
should be included in biomedical research with adequate protections); Lawrence O. Gostin,
Biomedical Research Involving Prisoners: Ethical Values and Legal Regulation, 297 JAMA
737, 739 (2007) (considering the risks and potential benefits of including prisoners in trials).
For a discussion on COVID-19 trials on prisoners see Nayanah Siva, Experts Call to Include
Prisons in COVID-19 Vaccine Plans, 396 LANCET, 1870, 1870 (2020).
84
Rebecca Dresser, Wanted: Single, White Male for Medical Research, 22 HASTINGS CTR.
REP. 24, 24 (1992); see also Katherine A. Liu & Natalie A. Dipietro Mager, Women’s
Involvement in Clinical Trials: Historical Perspective and Future Implications, 14
PHARMACY PRAC. 708, 709 (2016) (“[I]n previous decades the consideration and inclusion
of men overshadowed women in clinical research design and conduct.”).
80

510

Journal of Law and Public Affairs

[March 2021

II. HARM CAUSED BY EXCLUSION FROM RESEARCH
There are many negative consequences to a population being
excluded from research studies, some general to all excluded populations and
some particular to their characteristics. As DREDF explains: “The failure to
include or even identify people with disabilities when providers and health
care delivery systems are increasingly held to ‘evidence-based medicine’
standards means that individuals with disabilities face procedural delays and
barriers because there are few scientifically validated or administratively 'preauthorized’ treatments for people with disabilities.”85 It specified that “[t]here
is a dearth of scientifically validated information about how people with
various disabilities respond to common, leading, or cutting edge treatments,
whether they are medical, mental or behavioral health, or preventive
programs for smoking cessation or weight loss.”86
A. Population-Based Harm Caused to People with Disabilities by Exclusion
from Research
Because they are not included in the data gathering process, exclusion
of people living with disabilities from research causes considerable harm to
both the population living with disabilities as a whole and sub-populations of
those living with specific disabling conditions.
1. Harm from lack of information about conditions that affect the
general population but may impact people living with disabilities
differently
As a population, people living with disabilities are subject to the same
illnesses and conditions that affect the general population, such as heart
disease, but may be affected differently or may respond differently to
treatment.87 There are also examples of gaps in knowledge about behavioral
or educational issues specific to people living with disabilities. 88
85

DREDF Comment Letter, supra note 43.
Id.
87
See Beth Levine, Statins Are Safe to Use for Heart Protection in People with Rheumatoid
Arthritis, EVERYDAY HEALTH (Apr. 15, 2019), https://www.everydayhealth.com/rheumatoid-arth
ritis/rheumatoid-arthritis-statins-are-safe-heart-protection/ [https://perma.cc/R69H-EZ6B]
(reporting on a study of people with rheumatoid arthritis who take statins for heart disease).
88
Although the focus of this article is exclusion of people living with disabilities from research
not specifically related to their disabling condition, it is important to recognize that harm also
comes from lack of research about their disabling condition. For example, the National Institute
of Dental and Craniofacial Research reports a long list of health challenges faced by people with
developmental disabilities “such as autism, cerebral palsy, Down syndrome, and other cognitive
86
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One of the most important questions raised in looking at exclusion
from research is whether it causes disparate health outcomes or whether
those phenomena are correlative, in that they have a common cause. Dr.
Dianne Rios echoes this concern writing that because “people with
disabilities [are] one of the largest minority groups in the country,” their
exclusion from “research seriously limits the application of research
findings for a significant patient population.” 89
One of the ways that people with disabilities experience harm as a
population is being excluded from research related to conditions that may
affect them differently depending on the specific impact of their disabling
conditions. For example, finding that women with developmental disabilities
experienced worse health outcomes, a research team from Canada concluded
that “[o]ur findings suggest an urgent need to focus on reproductive and
perinatal health in women with IDD and to develop appropriate services and
policies to support their needs.”90
2. Harm from lack of knowledge specific to the disabling condition
There are several different ways that a person living with a disability
could be harmed by exclusion from a trial specific to their own disabling
condition. The first is the direct failure to conduct the trial at all. The second
is exclusion from a trial specific to their condition, but containing so many
conditions for participation that most people are ineligible. For example,
often trials are restricted to individuals with only one condition.91

disabilities” that “create challenges in accomplishing daily activities” which “often require a
special approach to dental care.” Developmental Disabilities & Oral Health, NAT’L INST. OF
DENTAL & CRANIOFACIAL RSCH. (Oct. 2020), https://www.nidcr.nih.gov/healthinfo/developmental-disabilities/more-info [https://perma.cc/ 22SD-4KXN].
89
Rios et al., supra note 37, at 2137 (citing Feldman et al., supra note 46, at 1003 (noting an
exclusion rate of 89.9%)).
90
Brown et al., supra note 49, at 15. For example studies of interventions to address a harmful
behavior prevalent among people with disabilities, see Teresa Iacono & Vanessa Murray,
Issues of Informed Consent in Conducting Medical Research Involving People with
Intellectual Disability, 16 J. APPLIED RSCH. INTELL. DISABILITIES 41 (2003); Bradley Crook,
Rose Tomlins, Ann Bancroft & Laura Ogi, ‘So Often They Do Not Get Recruited’: Exploring
Service User and Staff Perspectives on Participation in Learning Disability Research and
the Barriers that Inhibit It, 44 BRIT. J. LEARNING DISABILITIES 130 (2016).
91
For example, a study on the genetic and physical characteristics of individuals with a
genetic brain disorder that can interfere with intellectual development, Rett Syndrome, could
also be discriminatory if its protocol excludes participation of people with Rett Syndrome
who have other disabling conditions. See Alan K. Percy, Genetic and Physical
Characteristics of Rett Syndrome, CLINICALTRIALS.GOV (Mar. 16, 2017), https://clinical
trials.gov/ct2/show/NCT00299312 [https://perma.cc/U8BK-FA44] (describing a study on
Rett Syndrome treatment excluding individuals unable to travel to study sites).
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3. Dignitary harm
Exclusion from research is also exclusion from full participation in
society.92 As the Supreme Court held in Olmstead, it is not enough to avoid
discrimination; a government program must not act in a way that “perpetuates
unwarranted assumptions” that people with disabilities cannot “participat[e]
in community life.”93 This kind of rights-based language is reflected in the Irish
National Disability Authority’s (NDA) 2002 guidelines on how to foster
inclusion.94 For example, the National Institutes of Health in explaining its
mission to support biomedical research explains that “clinical research” is a
“social good.”95 The United Nation’s Convention on the Rights of People with
Disabilities has identified access to research as a strategic priority and a human
right that should be made equally available to people living with disabilities.96
B. Harm of Exclusion from Research That Provides Individual Participants
a Direct Benefit: The Case of Clinical Trials
The lack of approved drugs to treat COVID-19 or vaccines to protect
it creates an urgency to gain access to clinical trials reminiscent of the early
days of the AIDS epidemic. Using the slogan “Drugs into Bodies,” the grass
roots organization ACT UP argued that “with a new epidemic disease such
as AIDS, testing experimental new therapies is itself a form of health care
and that access to health care must be everyone's right.” 97 But in the days
Thank you to Professor Jacqueline Fox of South Carolina University School of Law for
pointing out this form of harm.
93
Olmstead v. L.C. ex rel. Zimring, 527 U.S. 581, 600 (1999).
94
NAT’L DISABILITY AUTH., GUIDELINES FOR INCLUDING PEOPLE WITH DISABILITIES IN
RESEARCH 8 (2002), http://nda.ie/nda-files/Guidelines-for-Including-People-with-Disabilitiesin-Research.pdf [https://perma.cc/EB3E-36FK] (discussing guidelines for effectively
including people with disabilities in all aspects of research that affect them).
95
The Need for Awareness of Clinical Research, NAT’L INSTS. OF HEALTH (Mar. 16, 2016),
https://www.nih.gov/health-information/nih-clinical-research-trials-you/need-awarenessclinical-research [https://perma.cc/Y6RT-84NW].
96
United Nations, supra note 27, at art. 4.
97
Douglas Crimp, Before Occupy: How AIDS Activists Seized Control of the FDA in 1988,
ATLANTIC (Dec. 6, 2011), https://www.theatlantic.com/health/archive/2011/12/before-occupyhow-aids-activists-seized-control-of-the-fda-in-1988/249302/ [https://perma.cc/8K5Y-MDPR];
see Marsha N. Cohen, Getting New Drugs to People with AIDS: A Public Policy Response
to Lansdale, 18 HASTINGS CONST. L.Q. 471, 481 (1991) (comparing some patients’ access
to experimental drugs for treating AIDS to other patients’ access to experimental cancer
therapies); Eileen Kelly, Expanding Prisoners' Access to AIDS-Related Clinical Trials: An
Ethical and Clinical Imperative, 75 PRISON J. 48, 49 (1995) (arguing that when “the most
promising [AIDS] treatments are experimental, community-standard care has come to mean
access to experimental drugs” and that “[i]f the goal is to provide to imprisoned people
medical care that is comparable to care available in the civilian community . . . then HIVinfected prisoners . . . must have access to clinical drug trials.”).
92
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since ACT UP, clinical trials have become an integral part of healthcare.
Writing of the effects of the low participation of African Americans in studies
of new cancer drugs, Dr. Kashif Ali, research head at Maryland Oncology
Hematology, stated that “minorities, including African Americans, miss out
on trials because of financial hurdles, logistical challenges and their lingering
distrust of the medical community due to a history of being victimized by
medical experimentation.”98 In particular:
“They’re potentially losing out on life-extending
opportunities because it’s one more option they no longer
have,” Ali said. “Especially when patients are in advanced
stages of cancer, treatments are like stepping stones: When
one stops working, you move on to the next.” Not joining a
trial can mean “you’ve lost life expectancy,” he said.99
Clinical trials that promise access to otherwise unavailable treatments
are often perceived to be of benefit to participants. This is especially true
when there are no approved effective treatments. 100 The most significant form
of study that may provide a benefit, however, is one that results in access to
otherwise unavailable medical care. 101
Every federally regulated research study must be approved by an
ethics committee that weighs the risks to the individual participants against
the expected benefits. 102 The starting point of “risk” is the risk that they
already experience. So, for example, a study involving a treatment for persons
already diagnosed with a serious illness is evaluated differently than the risk
of administering the same treatment to a “healthy volunteer.”103 The “benefit”
Caroline Chen & Riley Wong, Black Patients Miss Out on Promising Cancer Drugs,
PROPUBLICA (Sept. 19, 2018, 5:00 AM), https://www.propublica.org/article/black-patientsmiss-out-on-promising-cancer-drugs [https://perma.cc/PMP8-PN4R].
99
Id.
100
This is the current situation in regard to access to COVID-19 clinical trials but was also
the issue in the 1990s regarding access to trials of anti-retroviral. See Cohen, supra note 97,
at 481 (1991) (“Through a mechanism called the ‘compassionate IND,’ the FDA has long
allowed experimental drugs to be distributed to patients with no available alternative
therapies who were otherwise ineligible for the drug studies.”). Later, strong claims of
exclusion were made by prisoners with AIDS. Kelly, supra note 97, at 49 (arguing that
prisoners must be given access to AIDS-related clinical trials).
101
For other examples of clinical trials involving breakthrough drugs or interventions, see
Nancy S. Jecker, Aaron G. Wightman, Abby R. Rosenberg & Douglas S. Diekema, From
Protection to Entitlement: Selecting Research Subjects for Early Phase Clinical Trials
Involving Breakthrough Therapies, 43 J. MED. ETHICS 391, 392–93 (2017).
102
45 C.F.R. pt. 46 (2019).
103
See Patient Recruitment: Healthy Volunteers, CLINICAL CTR. (Apr. 2, 2020),
https://clinicalcenter.nih.gov/recruit/volunteers.html [https://perma.cc/BU2U-J4N3] (“Healthy
volunteers have always played a vital role in medical research. When developing a new
technique such as a blood test or imaging device, we need clinical research volunteers to help
us define the limits of ‘normal.’”).
98
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is also evaluated for each individual. In general, the less risk there is from
participating in the study, the less proof there needs to be of benefit.
C. Harm to Society from Excluding People with Disabilities
Another argument against exclusion from a research study is the harm it
does to society as a whole by invalidating results.104 The exclusion of the
population of people living with disabilities from research studies diminishes the
quality of the information generated by the results of the study being conducted.105
The second is a much broader category of research of conditions that
affect people with and without disabilities, but from which people with
disabilities have not been included. 106 For example, a team of obstetricians
interested in pregnancy outcomes among women with intellectual and
developmental disabilities reported that, “[t]o date, there is no research on the
maternal characteristics or pregnancy outcomes of women with [intellectual
and developmental disabilities] using a U.S. population-based sample.”107
Similarly, therapists wanting to compare the effectiveness of different
psychological interventions in the population of people with intellectual
disabilities found nothing to compare. There were no studies evaluating any
interventions with that population. 108
III. LOOKING FOR THE CAUSES OF EXCLUSION
Having documented exclusion and considered its harms, it is
important to identify what enables exclusion in order to develop legal
strategies to combat it. It is here that another kind of research becomes
important: that of scientists who not only document exclusion but seek to find

Feldman et al., supra note 46, at 998.
Paul Glasziou, Jan Vandenbroucke & Iain Chalmers, Assessing the Quality of Research,
328 BMJ 39, 40 (2004); Glenn T. Clark & Roseann Mulligan, Fifteen Common Mistakes
Encountered in Clinical Research, 55 J. PROSTHODONTIC RSCH. 1, 2–4 (2011).
106
See, e.g., Timothy I. Michaels, Jennifer Purdon, Alexis Collins & Monnica T. Williams,
Inclusion of People of Color in Psychedelic-Assisted Psychotherapy: A Review of the
Literature, BMC PSYCHIATRY, July 31, 2018, at 2 (describing exclusion of people of color
from testing of psychiatric drugs); Monnica T. Williams, Psychedelic Psychotherapy is
Coming: Who Will Be Included?, PSYCH. TODAY (Aug. 24, 2018), https://www.psychology
today.com/us/blog/culturally-speaking/201808/psychedelic-psychotherapy-is-coming-whowill-be-included [https://perma.cc/U6QN-RNE9] (“People of color have not been
meaningfully included in this [psychedelic] community.”).
107
Mitra et al., supra note 45, at 300.
108
Osugo & Cooper, supra note 53, at 619–20.
104
105
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the causal roots of exclusion. 109 Some of the barriers faced by people with
disabilities are caused by poverty. 110
A. Exclusion at the Starting Gate: Study Designs that Limit Subject Selection
The primary barrier to access to any research studies is the subject
selection process.111 Whether funded or regulated by law, the choice of who
participates is within the discretion of the researcher, just as employers
choose their employees and schools choose their students. 112 Researchers
identify the characteristics of the people they want and then proceed to first
recruit and then screen those interested before offering them the opportunity
to participate.113
In particular, the story of the experiences people with disabilities have as research subjects
shares many common themes with the story of African Americans. For an excellent overview
of these abuses, see CARL H. COLEMAN, JERRY A. MENIKOFF, JESSE A. GOLDNER & EFTHIMIOS
PARASIDIS, THE ETHICS AND REGULATION OF RESEARCH WITH HUMAN SUBJECTS 31–53 (2d ed.
2015). See generally DEPT. OF HEALTH, EDUC. AND WELFARE, NAT’L COMM’N FOR THE PROT. OF
HUMAN SUBJECTS OF BIOMEDICAL & BEHAVIORAL RSCH., THE BELMONT REPORT (1979), https://
www.hhs.gov/ohrp/sites/default/files/the-belmont-report-508c_FINAL.pdf [https://perma.cc/
98GD-5CXG] (memorializing some of the harm that people with disabilities suffered in the
United States during the Twentieth Century through their participation in medical research
and noting that this harm led to Congress soliciting guidance from ethicists on how to create
guidelines to protect vulnerable populations from exploitation).
110
See supra note 12 and accompanying text.
111
See generally Douglas MacKay, Fair Subject Selection in Clinical Research: Formal
Equality of Opportunity, 42 J. MED. ETHICS 672 (2016) (identifying issues with the standard
method of fair subject selection while proposing potential alternatives).
112
Edward A. Panacek & Cheryl Bagley Thompson, Sampling Methods: Selecting Your Subjects,
26 AIR MED. J. 75, 75 (2007) (“The first step in developing a full study protocol is having a clear
understanding of the research question to be answered. The next step is to have explicit definitions
of the independent and dependent variables of interest in the study. Then the target population can
be defined (i.e., who will qualify for the study?). This process involves generation of a list of
inclusion and exclusion criteria for potential study subjects.”); see also Elaine Larson, Exclusion
of Certain Groups from Clinical Research, 26 J. NURSING SCHOLARSHIP 185, 186 (1994)
(“Clinical trial investigators have often taken advantage of previously formulated cohorts such as
veterans, prisoners, members of the military, physicians, and nurses. Although such cohorts result
in skewed samples, they also greatly facilitate study recruitment and follow-up and are cost
effective.”); Craig A. Umscheid, David J. Margolis & Craig E. Grossman, Key Concepts of
Clinical Trials: A Narrative Review, 123 POSTGRADUATE MED. 194, 196 (2011), (“Although
RCTs seek to achieve internal validity by enrolling a relatively homogeneous population
according to predefined characteristics, narrow inclusion and exclusion criteria may limit their
external validity (or ‘generalizability’) to a broader population of patients with highly prevalent
comorbidities that may not be included in the sample cohort.”). This theme underscores why
an experimental treatment’s “efficacy” (i.e., a measure of the success of an intervention in
an artificial setting) may not translate into its “effectiveness” (i.e., a measure of its value
applied in the “real world”).
113
Financial Assistance for Mesothelioma Patients, MESOTHELIOMA APPLIED RSCH. FOUND.,
109
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Even if research is recognized as an activity that must include people
with disabilities, identifying the actual mechanism for doing so will be
important to moving from right to reality. Consistent with the principles of
“nothing about us without us,” the first step to addressing the elimination of
barriers will be to ask people living with disabilities. Here, again, the urgency
of precision medicine’s need for a comprehensive genetic database has put
them in the forefront. A recent survey generated by Dr. Maya Sabatello and
her team at Columbia seeking information about the attitudes of people with
disabilities regarding participation in genetic research serves as a model of
what can, and should, be done. The survey they administered over the internet
was “based on previous studies on attitudes about genomic research” but in
adapting it to the needs of people living with disabilities “[t]hroughout the
study, we consulted with experts with disabilities and national organizations
of people with disabilities about the survey’s content, format, and
programming (e.g., making the survey accessible to screen-readers, i.e.,
software programs that ‘translate’ text into speech for blind people).”114 The
survey’s creators “followed the principles of universal design,115 with the
goal of ensuring that the instrument was accessible, easy to understand, and
useful to people with a wide range of abilities.” 116
B. Exclusion as Protection: Historical Abuse of People with Mental Illness
and Developmental Disabilities in the Name Research
People with disabilities have had horrifying experiences as subjects of
research.117 At best, they have been treated as disposable and experimented on
https://www.curemeso.org/mesothelioma-treatment-plan/patient-support-and-resources/finan
cial-assistance-for-mesothelioma-patients/ [https://perma.cc/AM49-QLJ2] (last visited Jan.
24, 2021) (recognizing the cost of traveling to medical centers where trials take place and
describing financial assistance the Meso Foundation provides in the form of travel grants);
see also Watkins Bruner et al., supra note 13, at 708 (suggesting strategies for subjects who
have difficulty travelling to drug trial sites).
114
Maya Sabatello, Ying Chen, Yuan Zhang & Paul S. Appelbaum, Disability Inclusion in
Precision Medicine Research: A First National Survey, 21 GENETICS MED. 2319, 2320 (2019).
115
For an excellent and current analysis of the role of universal design in promoting
accessibility, see Ruth Colker, The Americans with Disabilities Act is Outdated, 63 DRAKE
L. REV. 787, 790 (2015) (“The ideal situation is one in which facilities and services are
initially designed in an accessible way. If this were always true, no special rules about
modifying facilities or services to create accessibility would be needed.”).
116
Sabatello et al., supra note 114, at 2320 (citing ROBERTA NULL, UNIVERSAL DESIGN:
PRINCIPLES AND MODELS (2013)).
117
See GEORGE J. ANNAS & MICHAEL A. GRODIN, THE NAZI DOCTORS AND THE NUREMBERG
CODE: HUMAN RIGHTS IN HUMAN EXPERIMENTATION 268 (1992) (discussing Nazi doctors’
justifications for experimentation, including the belief that certain populations, including
“the congenitally handicapped[,] . . . posed a biological threat to . . . the Reich.”); SUZANNE
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without their consent.118 At worst, they were subject to torture, including the
atrocities experienced by people with disabilities at the hands of doctors and
scientists complicit in the Nazi regime of the 1930s and 40s.119 Until very
recently, the focus of legal and ethical commentary on people with disabilities
as research subjects has been on developing appropriate protections for people
with developmental disabilities who may not be able to give fully informed
consent120 as much as it has been about concern for harm caused by exclusion.121
One of the most diverse populations within the already diverse
community122 of people living with disabilities is the group of people whose
E. EVANS, FORGOTTEN CRIMES: THE HOLOCAUST AND PEOPLE WITH DISABILITIES 38 (2004)
(“Physicians . . . conduct[ed] so-called scientific experiments on children that allowed them
to further their own research agendas. Children with cerebral palsy, Down syndrome, and
other neurological conditions were prime subjects for such experiments.”). See generally
HUGH GREGORY GALLAGHER, BY TRUST BETRAYED: PATIENTS, PHYSICIANS, AND THE
LICENSE TO KILL IN THE THIRD REICH (1990) (describing the murder of disabled victims in
Nazi research and euthanasia programs).
118
For accounts of these abuses, see COLEMAN ET AL., supra note 109, at 31–53 (describing,
among other things, “research scandals” in the United States and the Congressional and
regulatory response to them); Yearby, supra note 77, at 1223 (proposing an external system
to review proposals involving economically disadvantaged minority children as research
subjects); Medical Studies Still Exclude People of Color, R ESEARCH!AMERICA (June 2,
2017), https://www.researchamerica.org/ news-events/medical-studies-still-exclude-peoplecolor [https://perma.cc/5K5N-ZVG9] (“The history of research abuse is alive and well in
many of these communities—it lives through word of mouth.”); ADVISORY COMM. ON HUM.
RADIATION EXPERIMENTS, FINAL REPORT 3–4, 97–98, 178, 195, 207, 320–21, 330 (1995)
(reporting accounts of persons with disabilities exposed to radiation); David Wendler,
Raynard Kington, Jennifer Madans, Gretchen Van Wye, Heidi Christ-Schmidt, Laura A.
Pratt, Otis W. Brawley, Cary P. Gross & Ezekiel Emanuel, Are Racial and Ethnic Minorities
Less Willing to Participate in Health Research?, 3 PLOS MED. 201, 208 (2005) (reviewing
history of past abuses and concluding that there is insufficient data to substantiate the claim
that racial and ethnic minorities are less willing than non-minority individuals to participate
in health research).
119
For an informative and frequently updated source of information, see Nazi Medical
Experiments, U.S. HOLOCAUST MEM’L MUSEUM, https://www.ushmm.org/wlc/en/article.
php?ModuleId=10005168 [https://perma.cc/63JG-E9A5] (last visited Jan. 24, 2021).
120
In a 1996 JAMA article, Professor Rebecca Dresser noted the absence of specific
regulations establishing “standards and procedures for studies involving adults with mental
disabilities.” Rebecca Dresser, Mentally Disabled Research Subjects: The Enduring Policy
Issues, 276 JAMA 67, 67 (1996).
121
See Lisa Eckstein, Engaging Racial and Ethnic Groups in the Regulation of Research:
Lessons from Research in Emergency Settings, 12 HOUS. J. HEALTH L. & POL’Y 1, 4 (2011)
(discussing historically exploited populations and how research has risked causing harm to
those populations).
122
Gloria L. Krahn, Deborah Klein Walker & Rosaly Correa-De-Araujo, Persons with
Disabilities as an Unrecognized Health Disparity Population, 105 AM. J. PUB. HEALTH
S198, S198 (2015) (“People with disabilities are a diverse group who share the experience
of living with significant limitations in functioning and, as a result, often experience
exclusion from full participation in their communities.”).

518

Journal of Law and Public Affairs

[March 2021

disabling condition affects their thought processes.123 As a population, they
face discrimination, barriers to healthcare, and exclusion from research
similar to other people living with disabilities. One of the greatest hurdles to
including people with intellectual disabilities in research is the concern that
to do so would be unethical because the intellectually disabled may not be
competent to give consent and therefore would not be participating
voluntarily,124 or that they are vulnerable to exploitation and have been
exploited by researchers.125
The ethical concern about ability to consent translates into the legal
principal of competency. Professor Elyn Saks has defined this distinction by
referring to legal incompetency as a state of “literal incompetency” in which
they have been assigned a “court-appointed guardian” or have themselves
transferred decision making authority through a durable power of attorney. 126
In contrast, she points to the contemporary trend of involving people who
may be “developmentally disabled” or “demented” by using “Supported
Decision Making” which sets up a “collaborative process.”127 It is the latter
kind of decision making most relevant to decisions about participation in
research because the Common Rule requires that except in very rare
circumstances, all potential research subjects participate in the process of
decision making, whether they are legally able to give consent or not. 128
When a potential participant lacks legal capacity, researchers must obtain

123

Because disabilities that affect thought have many different origins, there is no standard
vocabulary.
124
This is an issue that researchers in Great Britain encountered and overcame. See generally
Ruth Northway, Joyce Howard & Lynne Evans, Participatory Research, People with
Intellectual Disabilities and Ethical Approval: Making Reasonable Adjustments to Enable
Participation, 24 J. CLINICAL NURSING 573, 580 (2014) (describing how the authors worked
with the ethics review committee to develop materials that would allow research to go
forward and recommending to others that “[r]ather than viewing the process as fixed, and
systems as precluding the participation of people with intellectual disabilities, potential
barriers to participation and to ethical approval were anticipated and strategies put in place
to reduce or overcome them.”).
125
See Kevin Rak, Alicia K. Matthews, Gabriela Peña, Wendy Choure, Raymond A. Ruiz,
Sandra Morales, Amparo Castillo, Jackie Soo & Emily E. Anderson, Priority Populations
Toolkits: Enhancing Researcher Readiness to Work with Priority Populations, 4 J. CLINICAL
& TRANSLAT’L SCI. 28, 28–35 (2019) (including people with disabilities as a priority
population and evaluating the efficacy of researchers’ Priority Populations Toolkits).
126
Elyn R. Saks, Competency to Decide for Another, 30 HEALTH MATRIX: J. L.-MED. 1, 3–4
(2020) [hereinafter Saks, Decide for Another] (discussing mechanisms for assessing the
competency of substitute decision makers themselves to make decisions about medical care); see
also Elyn R. Saks, Competency to Refuse Medication: Revisiting the Role of Denial of Mental
Illness in Capacity Determinations, 22 S. CAL. REV. L. & SOC. JUST. 167, 167–68 (2013)
(discussing the need to respect the decisions of people who deny that they are mentally ill).
127
Saks, Decide for Another, supra note 126, at 4–5.
128
45 C.F.R. § 46.117(c)(1) (2019).
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their “assent” to participate rather than “consent.” 129 As a result, even people
who have been found incompetent for some purposes under the laws of their
state must be asked for their assent. 130Again, this process of collaboration
between researchers, participants, and surrogate decision makers is well
developed in the U.K., where it is necessary to comply with the mandate of
including people who are not legally competent as participants in research. 131
Professor Saks points out that even when an individual “with [a] severe
developmental disability who has the mental age of a one-year-old” or “a
person in the midst of a psychotic episode with delusions and hallucinations”
should “at least” be asked “what he or she wants.” 132
They are perceived as adding cost and difficulty to the study as well
as possibly invalidating the generalizability of the results.133 None of the
FDA’s mandates to diversify the population of people enrolled in clinical
trials includes people with disabilities, let alone with any form of mental
disability. As a result, they are frequently left out.
This is harmful for all the reasons that exclusion is harmful, but
especially so in clinical drug trials because people living with disabilities will
be taking drugs that were never tested on them. While the inclusion of people
129

Id. § 46.402; see also Informed Consent Tips, HHS.GOV (March 16, 1993), https://www.
hhs.gov/ohrp/regulations-and-policy/guidance/informed-consent-tips/index.html [https://perma.
cc/5ABA-BWLN] (listing suggested best practices on how to obtain informed consent from
research subjects).
130
See, e.g., Children's Assent, NAT’L CANCER INST. https://www.cancer.gov/aboutcancer/treatment/clinical-trials/patient-safety/childrens-assent
[https://perma.cc/CLC7D9BP] (last updated March 11, 2020) (describing how to obtain assent, rather than informed
consent, from children taking part in clinical trials).
131
See Shepherd et al., Protection by Exclusion, supra note 35, at 6 (showing a thorough
review of the issues raised, and addressed, in the U.K. regarding participation of people with
intellectual disabilities in research); Shepherd et al., Lacking Capacity, supra note 35, at 8–
9 (analyzing the written information given to proxy decision makers for permission to
participate in research trials).
132
Saks, Decide for Another, supra note 126, at 6–7; see also id. at 8, 10 (proposing her own
“gold” standard of competency to make decisions, which requires “(1) ‘understanding,’ in
the sense of comprehending what is being told to one; (2) ‘appreciating,’ in the sense of
forming acceptable beliefs about what one is told; (3) ‘reasoning’ with the information; and
(4) ‘evidencing a choice’” because “[w]ith this standard, ‘understanding’ and ‘appreciating’
require different skills—comprehension and belief-formation”).
133
For a discussion noting both the exclusion of children with intellectual disabilities and
possible reasons for this exclusion, see James R. Christensen, Beth S. Slomine, Faye S.
Silverstein, Kent Page, Richard Holubkov, J. Michael Dean & Frank W. Moler, Cardiac
Arrest Outcomes in Children With Pre-existing Neurobehavioral Impairment, 20 PEDIATRIC
CRITICAL CARE MED. 510, 516 (2019) (addressing directly the need to include children with
intellectual disabilities in research studies and discussing challenges of comparing children
with and without pre-existing intellectual disabilities in studying outcomes of children who
experienced prolonged comas, but arguing that “this group’s inclusion . . . was both feasible
and informative”).
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with developmental or intellectual disabilities who cannot, themselves, give
consent for research presents similar issues regarding their vulnerability to
exploitation, the exclusion of people with diagnosed mental illness is more
directly discriminatory and just as illegal. It is also widespread.
In her article titled “Why do clinical trials exclude depressed
people?,” journalist Erica Westly addressed the issue in the context of the
failure to test Chantix, a drug designed to assist people in quitting smoking,
with a population of people who have been diagnosed with depression. 134 As
a result, it was not until after the drug was approved that evidence emerged
that it might increase the risk of suicide. She discovered that the exclusion of
people with depression from clinical trials was common. She was told that
“[a]dherence is often an issue with depressed participants.” In addition to
exclusion from smoking trials, Ms. Westly was also told that “excluding
participants with depression from weight loss studies amounts to
discrimination because it denies them access to potentially helpful
treatments.”135 Doing her own research into the issue, she found that, “[o]f
38 actively recruiting large-scale late-stage studies known as Phase 3 clinical
trials, 21 excluded people with mental illness, and 10 did so for depression
specifically.”136
Celia Fisher, director of the Center for Ethics Education at Fordham
University, has been a longtime advocate for inclusion.137 Responding to a
question about the reluctance to include people with disabilities in research
studies, she stated that “[m]any times, review boards think people with
intellectual disabilities should be excluded so we can protect them from
coercion or not really understanding the research they’re in.”138
However, that protection can cause more harm than good because
“treatments for different health problems are not always effective in all
populations, so if people with intellectual, or other disabilities, are not
included then it violates the principle of justice, because they don’t have the
opportunity to benefit from information that can be derived from that
research.”139 Instead, she advocates that people with intellectual disabilities
be included in decision making by developing consent procedures that

134

Erica Westly, Why Do Clinical Trials Exclude Depressed People?, REUTERS (Mar. 18, 2011,
7:21 AM), https://www.reuters.com/article/us-trials/why-do-clinical-trials-exclude-depressedpeople-idUSTRE72H31320110318 [https://perma.cc/X6F2-2LHM].
135
Id.
136
Id.
137
Joshua Howgego, View on Disability: Trials Exclude Vulnerable People, SCIDEV.NET, (Feb.
14, 2017), https://www.scidev.net/global/vulnerability/analysis-blog/view-on-disability-trialsexclude-vulnerable-people.html [https://perma.cc/JEV6-V8GN].
138
Id.
139
Id.
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“involve[] engaging adults with mental disorders as partners in creating
respectful and compassionate consent procedures.” 140
Given this history, it is not surprising that they would be reluctant
about participating, and perhaps fears of past abuse would deter current
researchers.141 Like the reluctance to participate based on past abuse often
attributed to African-American rates of participation, 142 people with
disabilities, and particularly parents of children with disabilities, have sound
reasons to be cautious.143
Although exploitation and exclusion may seem to be mutually
exclusive, they are, in fact, different sides of the same coin. Both reflected
the lived experience of populations which still share the same characteristics
that made them vulnerable to exploitation. 144 This is especially true of people
See Celia B. Fisher, A Goodness-of-Fit Ethic for Informed Consent, 30 FORDHAM URB.
L.J. 159, 171 (2002) (arguing that informed consent policies for adults with mental disorders
need to reflect a relational approach in terms of a “goodness-of-fit” between patient
characteristics and consent).
141
For arguments on why past abuses should not result in exclusions from research, see
Hoffman, supra note 83, at 48.
142
VIVIAN W. PINN, CARL ROTH, ANGELA C. BATES, CARLOS E. CABAN & KIM JAREMA,
MONITORING ADHERENCE TO THE NIH POLICY ON THE INCLUSION OF WOMEN AND
MINORITIES AS SUBJECTS IN CLINICAL RESEARCH: COMPREHENSIVE REPORT: TRACKING OF
HUMAN SUBJECTS RESEARCH AS REPORTED IN FISCAL YEAR 2004 AND FISCAL YEAR 2005, at
78 (2006); Anabella G. Castillo, Lina Jandorf, Linda D. Thélémaque, Sheba King &
Katherine Duhamel, Reported Benefits of Participation in a Research Study, 37 J. CMTY.
HEALTH 59, 60 (2011). See generally Deborah J. Toobert, Lisa A. Strycker, Russell E.
Glasgow, Diego Osuna, Alyssa Tinley Doty, Manuel Barrera, Jr., Cristy R. Geno & Debra P.
Ritzwoller, ¡Viva Bien!: Overcoming Recruitment Challenges in a Multiple-Risk-Factor
Diabetes Trial, 34 AM. J. HEALTH BEHAV. 432 (2010).
143
Eric G. Yan & Kerim M. Munir, Regulatory and Ethical Principles in Research Involving
Children and Individuals with Developmental Disabilities, 14 ETHICS & BEHAV. 31, 32–33
(2004) (reviewing the history of research involving children with developmental disabilities,
including hepatitis vaccine research at Willowbrook State School). Unfortunately, many of
the scientists participating in the Willowbrook studies continued to argue that because the
children would have been exposed to hepatitis anyway, the benefits to all similarly situated
children from the discovery of an effective treatment and then vaccine for Hepatitis B justified
experiment. See Saul Krugman, The Willowbrook Hepatitis Studies Revisited: Ethical Aspects,
8 REVS. INFECTIOUS DISEASE 157, 161 (1986) (“While I agree with the critics of medical
research who state that the ends (successful accomplishments) do not justify the means, I
believe that this generalization does not apply to our Willowbrook studies.”).
144
See Yearby, supra note 77, at 1223 (proposing an external system to review proposals
involving “economically disadvantaged minority children as research subjects”); Medical Studies
Still Exclude People of Color, supra note 118 (“The history of research abuse is alive and well in
many of these communities—it lives through word of mouth.”); Jill A. Fisher & Corey A.
Kalbaugh, Challenging Assumptions About Minority Participation in US Clinical Research, 101
AM. J. PUB. HEALTH 2217, 2221 (2011) (“Regardless of the reasons for the overrepresentation of
minorities in phase I trials and the continued underrepresentation of minorities in phase III trials,
we need to consider these phenomena from an ethical standpoint.”).
140
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with intellectual disabilities. 145 But while any proposal for greater inclusion
must incorporate an ongoing recognition of their vulnerability and risk of
exploitation, the harm of complete exclusion is not justified. 146
C. Addressing Perceptions That People Living with Disabilities Are Not
Interested in Research
Some have attributed the failure to include people living with
disabilities from research to a belief that, because of the history of past abuse,
they do want to be included. 147 Similar claims are made about African
Americans: that they choose not to participate because of concern that they
will be exploited. As a result, they are not recruited and their absence from
research populations is assumed to be a matter of their own choice rather than
of their exclusion. The research done recently on the attitudes of people living
with disabilities about participating in research is quite similar to the much
more extensive information available about African Americans. People living
with disabilities are aware of and concerned about past abuse that occurred
as part of research studies, but they are not categorically opposed to
participating in research.
In the first study ever conducted regarding the interest of people with
disabilities in participating in precision medicine research (PMR) that
involved taking genetic samples, Dr. Maya Sabatello and her team at
Columbia found that “[p]eople with disabilities in our study, across
For an overview of research on abuse of people with disabilities, see CHILD WELFARE
INFORMATION GATEWAY, U.S. DEP’T OF HEALTH AND HUMAN SERVS., THE RISK AND
PREVENTION OF MALTREATMENT OF CHILDREN WITH DISABILITIES (Jan. 2018), https://www.
childwelfare.gov/pubPDFs/focus.pdf
[https://perma.cc/TV5J-DLUX];
Abuse
and
Exploitation of People With Developmental Disabilities, DISABILITY JUST., http://
disabilityjustice.org/justice-denied/abuse-and-exploitation/ [https://perma.cc/B27M-DP5S]
(last visited Feb. 15, 2021); Sexual Abuse of People with Disabilities, RAINN, https://
www.rainn.org/articles/sexual-abuse-people-disabilities [https://perma.cc/2KDU-ZGYY] (last
visited Feb. 14, 2021); see also Fisher & Kalbaugh, supra note 144, at 2221 (suggesting that
discrimination is an explanation for under-represented minorities being over-represented in
trials where there is little benefit).
146
For a history of the development of human subject research regulation in the United
States, see Margaret J. Neff, Informed Consent: What Is It? Who Can Give It? How Do We
Improve It?, 53 RESPIRATORY CARE 1337 (2008).
147
See 1 WOMEN AND HEALTH RESEARCH: ETHICAL AND LEGAL ISSUES OF INCLUDING
WOMEN IN CLINICAL STUDIES 36 (Anna C. Mastroianni, Ruth Faden & Daniel Federman
eds., 1994) (“The roots of protectionism go deeper than those of greater access. For example,
in the wake of revelations that government-funded research projects engaged in unethical
treatment of participants . . . policies were formulated to protect human volunteers. Policies
grounded in protectionist considerations contributed to the later exclusion of pregnant
women and women of childbearing potential from some clinical studies, most notably, early
phase drug trials.”).
145
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racial/ethnic groups, expressed high support for PMR and willingness to
participate in a longitudinal study.”148 But she also found that despite their
interest, 76% of the 1294 participants “identified 3 to 8 barriers” to
participation.149 Some of these barriers were directly linked to past abuse.
Forty-two percent of respondents endorsed the statement that “PMR might
be used to harm people like me.”150 Other barriers were ones directly related
to what they face in accessing any healthcare including “physical obstacles,”
“the space and equipment in clinics and health-care facilities are not
accessible for me” (56%), and “transportation to health-care facilities is
difficult” (53%).151 Large minorities of participants selected:
“communication with health professionals is difficult for me” (44%),
“information about medical research is not accessible to me” (43%). 152 And
the last group reflected concerns about cost such as “transportation to
healthcare facilities is too expensive.”153
D. Lack of Researchers Who Themselves Live with Disabilities
Another factor identified as posing a barrier to inclusion is the lack of
researchers who, themselves, identify as people with disabilities.154 This is
attributable to discrimination at every stage in the education pipeline, but is
particularly visible by the time individuals who might be interested in
pursuing a scientific career graduate from college. A research study
conducted by the National Center for Educational Statistics found that
although “relatively equal numbers of students with and without disabilities
enter college with the intention to major in a STEM field,” few end up
graduating with a STEM degree because of attrition along the way, 155
Sabatello et al., supra note 114, at 2324–25.
Id. at 2323.
150
Id.
151
Id.
152
Id.
153
Id.
154
See Williams, supra note 106 (“One factor contributing to low representation is the lack of
cultural inclusivity within the research community itself. Historically, psychedelic research has
been predominated by White men and there have been few people of color in positions
of leadership.”); Natalie Jacewicz, Why Are Health Studies So White?, ATLANTIC (June 16,
2016), https://www.theatlantic.com/health/archive/2016/06/why-are-health-studies-so-white/
487046 [https://perma.cc/S4Z2-7SRR] (“The committees that distribute National Institutes
of Health dollars, for example, are made up of scientists who have received grants
themselves. ‘The scientists that are reviewing the grants are primarily white males,’ said
Burchard. ‘They’ll say, “This is my friend. He’s white, trying to get blacks, and he can’t do
it. Let’s give him a pass.”’”).
155
Rachel Friedensen, STEM Climate for Students with Disabilities, AM. COUNCIL ON EDUC.:
HIGHER EDUC. TODAY (May 23, 2018), https://www.higheredtoday.org/2018/05/23/stem148
149
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attributable to a failure to provide appropriate accommodations.156 In
response to this gap, CAST, a nonprofit education research and development
organization, recommends that “[o]verall, STEM departments should
adopt Universal Design for Learning principles, which will make it easier to
address the needs of students with and without disabilities and offer the best
possible support to the largest number of students.”157 These factors are very
similar to those recognized as barriers to inclusion of other underrepresented
populations in both STEM degrees and STEM research careers.158 While the
NIH is making efforts to address the lack of gender and ethnic diversity
among those conducting research, so far there are no similar efforts involving
people with disabilities.159
Although this issue has yet to be researched, another reason for
exclusion from research may be directly related to the experiences of people
with disabilities in receiving medical care because “77% of patients who
participate in a trial learned about it from their health care provider.” 160
E. Exclusion Because of Study Design
The language of the primary statute addressing disability-based
discrimination is one of access and inclusion and calls for the removal of

climate-students-disabilities [https://perma.cc/PF36-WD9X] (“[A]bout 25 percent of
students in each group have a declared STEM major.”).
156
See id. (“In some instances, instructors can be hostile or indifferent to providing requested
accommodations; in others, disability services professionals who help students navigate the
accommodations system decide which accommodations would be well-received by
instructors, whether or not the students would benefit from them. Additionally, some
instructors report that disability services sometimes fail to offer STEM-appropriate
accommodations guidance.”).
157
Id. Friedensen references Universal Design for Learning Principles. Those principles can be
found on CAST’s website. About Universal Design for Learning, CAST, http://www.cast.org/
our-work/about-udl.html [https://perma.cc/A2JU-8AAR] (last visited Feb. 26, 2021).
158
Indeed, researchers looking at disparities in research funding for Black applicants attribute the
lower rate of funding for Black projects to the fact that “African American scientists may be more
likely to pursue research in topic areas such as community-oriented research on disease
prevention, for example, versus more microscopic-level research on cellular mechanisms or the
basis of genetics. Those population-based topics aren’t being funded as readily.” Emily Vaughn,
What’s Behind the Research Funding Gap for Black Scientists?, NPR (Oct. 18, 2019, 12:17 PM),
https://www.npr.org/sections/health-shots/2019/10/18/768690216/whats-behind-the-researchfunding-gap-for-black- [https://perma.cc/HSL6-8UYL].
159
See Including Women and Minorities in Clinical Research Background, NAT’L INSTS.
HEALTH: OFF. RSCH. ON WOMEN’S HEALTH, https://orwh.od.nih.gov/womens-health/clinicalresearch-trials/nih-inclusion-policies/including-women-and-minorities [https://perma.cc/3BA4BSGC] (last visited Feb. 26, 2021) (describing policies implemented to better include women
and minorities in clinical research).
160
The Need for Awareness of Clinical Research, supra note 95.
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barriers.161 As a result, the most visible features of the ADA are alterations
to physical objects whose original form made them difficult for people with
disabilities to use. Things like ramps, elevators, talking street signs, and
frustration-free packaging are all associated with addressing disability-based
discrimination. However, not all barriers to inclusion are physical.
The primary recommendation of Dr. Rios and other advocates of
inclusion is that researchers adopt “universal design” principles which
“would provide multiple means of representation, actions, expression and
engagement” that would create “physical and social research environments”
that are “accessible and appropriate for all children.” 162
Dr. Rios and her team build on the work of Moore and Williams to
“provide[] a conceptual basis for accessible research design” based on
already existing recommendations that track the Americans with Disabilities
Act’s mandates for preventing discrimination. 163 Building on a growing body
of available research on making both medical care and research studies more
accessible to people with disabilities, they suggest “3 levels of implementation:
(1) universal design, (2) accommodations, and (3) modifications.”164
Drawing an analogy to how legal mandates have resulted in the
development of guidelines to reduce barriers to full participation in society,
Rios highlights guidelines for making research accessible. 165 She ends with a
call for action stating that:
Federal funding agencies, such as the NIH and National
Institute on Disability, Independent Living, and Rehabilitation
Research must emphasize the importance of inclusion of people
with disabilities, not only as a civil rights issue but also to
enhance the scientific integrity and interpretability of research
findings to real-world clinical and policy applications.166

161

42 U.S.C. § 12182(b)(2)(A)(iv); see also AMERICANS WITH DISABILITIES: PRACTICE AND
COMPLIANCE MANUAL § 4:185 (database updated Feb. 2021) (describing the requirements
for establishing an architectural barrier claim).
162
Feldman et al., supra note 46, at 1008; see also Williams & Moore, supra note 36, at 3
(proposing three rules for universal research design: “(i) plan multiple options for people to
learn about, respond to, and arrive at opportunities to participate in research . . . (ii) provide
multiple means to communicate the information in research instruments and instructions for
participants . . . and (iii) provide multiple means of responding to research instruments and
self-management interventions”).
163
Rios et al., supra note 37, at 2138.
164
Id.
165
Id. at 2139.
166
Id. at 2143.
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F. Reasons for Exclusion of People with Disabilities Drawn from Exclusion
of Other Populations
Some of the barriers that make it difficult for people living with
disabilities to participate in research are similar to those of underrepresented
populations.167 For example, a report commissioned by the FDA notes that
low income is one of the primary barriers to recruiting a diverse population
for research studies because “ethnic minority groups are affected more by
poverty and lower socioeconomic status.” 168 These same factors affect people
living with disabilities who are also more likely to be low income 169 and thus
face financial barriers to participating in studies which require travel. 170

See generally Jennifer Harris & Keri Roberts, Challenging Barriers to Participation in
Qualitative Research: Involving Disabled Refugees, 2 INT’L J. QUALITATIVE METHODS 14
(2003) (discussing barriers to conducting interviews in qualitative studies with disabled
refugees and asylum seekers); Rebecca Luebbert & Amelia Perez, Barriers to Clinical
Research Participation Among African Americans, 27 J. TRANSCULTURAL NURSING 456
(2016) (discussing the barriers to recruiting African American participants); Ryan D. Nipp,
Hang Lee, Elizabeth Powell, Nicole E. Birrer, Emily Poles, Daniel Finkelstein, Karen
Winkfield, Sanja Percac-Lima, Bruce Chabner & Beverly Moy, Financial Burden of Cancer
Clinical Trial Participation and the Impact of a Cancer Care Equity Program, 21
ONCOLOGIST 467 (2016) (discussing financial barriers to participation in cancer trials).
168
See Isabelle Yates, Jennifer Byrne, Susan Donahue, Linda McCarty & Allison Mathews,
Representation in Clinical Trials: A Review on Reaching Underrepresented Populations in
Research, ASS’N CLINICAL RSCH. PROS. (Aug. 10, 2020), https://acrpnet.org/2020/08/10/
representation-in-clinical-trials-a-review-on-reaching-underrepresented-populations-in-re
search [https://perma.cc/E64Y-MKEG] (“In a prospective survey study conducted in 2016,
patients with household annual incomes below $50,000 were 27% less likely to participate
in clinical trials, and as income dropped, so did the likelihood of trial participation.”); Joseph
M. Unger, Julie R. Gralow, Kathy S. Albain, Scott D. Ramsey & Dawn L. Hershman, Patient
Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study, 2 JAMA
ONCOLOGY 137, 137–38 (2016) (“Our research group previously found that patients with
annual household incomes below $50[,]000 were 27% less likely to participate in clinical
trials.”).
169
See Disability & Socioeconomic Status, AM. PSYCH. ASS’N, https://www.apa.org/pi/
ses/resources/publications/disability [https://perma.cc/6WL7-TAFK] (last visited Jan. 24,
2021) (“[P]eople with disabilities remain overrepresented among America’s poor and
undereducated.”).
170
OFF. RSCH. ON WOMEN’S HEALTH, NAT’L INSTS. HEALTH, REVIEW OF THE LITERATURE:
PRIMARY BARRIERS AND FACILITATORS TO PARTICIPATION IN CLINICAL RESEARCH 1 (n.d.),
https://orwh.od.nih.gov/sites/orwh/files/docs/orwh_outreach_toolkit_litreview.pdf [https://
perma.cc/KT4H-4JFW] (“The most often cited barrier to participation was related to study
burden. When a potential participant has no car and buses and taxis are difficult to access or
are too costly, the prospect of traveling to a clinical facility for research purposes may present
a formidable obstacle.”).
167
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Because access to clinical trials is primarily by physician referral, 171
physician bias is also a significant issue in attracting diverse participants. 172
Other barriers may be specific to their disabling condition such as
those that impair the ability to travel. 173 But there are some forms of
discrimination which are particular to people with disabilities, such as
assumptions that “their quality of life is poor or that they are unhealthy
because of their impairments.”174 Other assumptions include perceptions that
participants will be difficult to communicate with or will have trouble
following instructions.175 Of course, these barriers are exactly the type that
federal law requires those bound by the ADA to overcome through
reasonable accommodations.

See AM. CANCER SOC’Y CANCER ACTION NETWORK, BARRIERS TO PATIENT ENROLLMENT
THERAPEUTIC CLINICAL TRIALS FOR CANCER: A LANDSCAPE REPORT 24 (2018),
https://www.fightcancer.org/sites/default/files/National%20Documents/Clinical-Trials-Land
scape-Report.pdf [https://perma.cc/27R9-AUWS] (“Physicians’ clinical trial referral
behavior has not only the ability to affect overall accrual, but it can also affect disparities in
accrual. In studies of breast cancer patients, the rate at which women under the age of 65
were offered clinical trials was up to twice that of older women (68% vs 34%) and a similar
two-fold referral difference was seen between black and white women.”).
172
See generally Chloë FitzGerald & Samia Hurst, Implicit Bias in Healthcare
Professionals: A Systematic Review, BMC MED. ETHICS 1 (2017) (describing physicians’
implicit biases); Sheba George, Nelida Duran & Keith Norris, A Systematic Review of
Barriers and Facilitators to Minority Research Participation Among African Americans,
Latinos, Asian Americans, and Pacific Islanders, 104 AM. J. PUB. HEALTH e16 (2014),
(emphasizing the need to recruit diverse populations for research studies).
173
See Common Barriers to Participation Experienced by People with Disabilities, CTRS.
FOR DISEASE CONTROL & PREVENTION: DISABILITY & HEALTH PROMOTION,
https://www.cdc.gov/ncbddd/disabilityandhealth/disability-barriers.html [https://perma.cc/
8RJ6-TF2Y] (last updated Sept. 16, 2020) (“Transportation barriers are due to a lack of
adequate transportation that interferes with a person’s ability to be independent and to
function in society.”). Writing from a personal perspective, Kyle Bryant explains that he
makes the effort to participate in a clinical trial despite physical difficulties getting to the
hospital where it occurs because “[m]any clinical trials in general fail because of lack of
participation. So with numbers like in [his disabling condition], each person has a big
responsibility to do their part.” Kyle Bryant, Why Participate in Clinical Trials?, HUFFPOST
(Dec. 6, 2017), http://www.huff ingtonpost.com/kyle-bryant/why-participate-inclinic_1_b_9712248.html [https://perma.cc/ 6S48-G4UC].
174
Common Barriers to Participation Experienced by People with Disabilities, supra note 173.
175
Id. (“Communication barriers are experienced by people who have disabilities that affect
hearing, speaking, reading, writing, and or understanding, and who use different ways to
communicate than people who do not have these disabilities.”).
171
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G. Justifications for Exclusion
1. Adding cost to the study
Concerns about cost are expressed in study designs intended to
achieve useful results as quickly and efficiently as possible by excluding an
array of factors that might add to cost or time.
Barring the inclusion of people with disabilities because of the
increased resource burden is similar to, and just as illegal as, limiting access
to healthcare.
Over the last several years, researchers interested in finding reasons
for exclusion have reviewed study designs that excluded people with
disabilities to see what modifications would be required and what affect
inclusion would have on the study’s results.
2. Affecting validity of results
Another aspect of discrimination relevant to people with disabilities
is the belief that they are fundamentally different. Just as the Tuskegee
Syphilis experiment was based on racist views about differences in
physiology, some researchers believe that people with disabilities are
different. Dr. Rimmer found that, in examining the criteria for inclusion of
the studies they reviewed, “researchers often, if not always, use a ‘preexisting
condition’ or disability as one of [their] exclusion criteria, thus limiting the
generalizability of these findings for people with disabilities.” 176
Concerns about the ability of people with disabilities to meet the
requirements of the study combine factors of cost and physiology. They are
expressed by the criteria for inclusion in the study itself.
As early as 2000, Drs. Allan Meyers and Elena Andresen pointed out
the need to change the methods researchers were using so as to make them
accessible.177
In looking for reasons why people with disabilities were excluded, Dr.
Rios found that many studies have “overly rigid inclusion and exclusion
criteria” that screen out people with disabilities without consideration of
whether the individual’s disabling condition would impact their ability to

Rimmer et al., supra note 51, at 2.
See Allan R. Meyers & Elena M. Andresen, Enabling Our Instruments: Accommodation,
Universal Design, and Access to Participation in Research, 81 ARCHIVES PHYSICAL MED. &
REHAB. S5, S8 (2000) (“To our knowledge, no one has filed suit to be included in surveys,
but we believe that there are reasonable legal bases for doing so, eg, many surveys are
designed and implemented with public money.”).
176
177
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participate.178 Summarizing these criteria, she wrote that the requirements that
resulted in excluding people with disabilities were often “poorly justified.”179
Like Dr. Rios, though, Dr. Feldman and his research team identified
“several modifications that probably would not have invalidated the findings”
of the studies they reviewed. 180 Dr. Feldman further rejected arguments
against modification by stating that “[t]he possibility of differences in scores
based on instruction and test delivery” would not invalidate the findings.181
Instead, he noted that these factors “could be examined in a precursor study
or statistically analysed in the same study.”182
Dr. Feldman and his research team studied the “justifications for
excluding children with disabilities as participants” in the studies they
reviewed and found that only “about one-third of the studies explicitly stated
and provided a reason” for exclusion. 183 Reasons for exclusion included:
participants being “incapable of meaningful participation, concerns about the
validity of psychometric testing, research design concerns, [concerns that
participants] would not be able to complete surveys and questionnaires
independently, research focuses on normative sampling, and [the desire] to
minimise disruptions to the study.”184
Dr. Feldman concluded that in “the majority of studies that explicitly
stated reasons for exclusion,” these reasons were only “justified[] in the
absence of possible accommodations.” 185
IV. DEVELOPING A LEGAL RESPONSE TO EXCLUSION: THE AMERICANS
WITH DISABILITIES ACT
Having considered the evidence of exclusion of people living with
disabilities from research studies, the harm caused by exclusion, and some of
Rios et al., supra note 37, at 2138; Feldman et al., supra note 46, at 1006.
Rios et al., supra note 37, at 2138.
180
See Feldman et al., supra note 46, at 1006 (citation omitted) (giving as examples
“simplifying the questions or task; using visuals to help participants understand difficult
concepts or procedures; using different presentation modes such as Braille, sign language,
communication devices or dictation; accepting alternative modalities for participant
responses; providing a scribe for pencil/paper work; and offering frequent breaks.”).
181
Id.
182
Id. Using different modalities for collecting research data is a fairly common research
challenge with many well-developed solutions. See, e.g., Benjamin Herold, Comparing
Paper-Pencil and Computer Test Scores: 7 Key Research Studies, EDUC. WK. (Feb. 4, 2016),
https://www.edweek.org/teaching-learning/comparing-paper-pencil-and-computer-test-scores7-key-research-studies/2016/02 [https://perma.cc/G8DK-C6P2] (reviewing techniques,
like score adjustments and comparability analysis, for comparing the results of exams taken
on paper versus exams taken on a computer).
183
Feldman et al., supra note 46, at 1002.
184
Id.
185
Id. (emphasis omitted).
178
179
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the possible reasons for exclusion, it is now possible to look directly at how
this exclusion can be remedied. This section of the article identifies two
primary approaches: 1) applying the anti-discrimination provisions of the
Americans with Disabilities Act186 and 2) incorporating the population of
people living with disabilities into existing statutory provisions to diversify
the population participating in the most common forms of research conducted
in the United States.187
A. An Overview of Applying Legal Analysis to Disability-Based
Discrimination in Research Studies
In order to illustrate how existing provisions of the ADA already
prohibit disability-based discrimination, this section takes a functional
approach by reviewing the most common settings in which research is
conducted and then identifying the significant features that trigger the
protection of existing laws prohibiting disability-based discrimination. It
starts with the most common settings—research studies conducted and
funded by the federal government—and then considers the more complex,
more varied scenarios of biomedical research involving the development of
drugs, vaccines, and devices. In so doing, it makes no attempt to offer a
comprehensive overview of the ADA or disability law.188 Instead, this article
is intended to inspire action and awareness, not suggest litigation strategies
to lawyers already expert in protecting the rights of people living with
disabilities either as individuals or collectively as a class. 189
For an overview of the purposes of the ADA, see 29 U.S.C. §§ 701–796.
The ADA does not extend outside the territorial limitations of the United States. Research
conducted or funded by the federal government is subject to U.S. human subject protection
law so if inclusion mandates were incorporated into that law, they would apply overseas. Nor
has Congress required research pursuant to an application for permission from the FDA to
market a new drug be conducted according to U.S. law. Jennifer S. Bard, A Taxonomy for
Analyzing Legal and Ethical Issues Arising When Conducting Human Subject Research
Outside the Borders of One’s Own Country, 37 HOUS. J. INT’L L. 1, 41 (2015). For a review
of the regulation of overseas research see id.
188
There are certainly extensive resources doing just that. See Derek Warden, Methods of
Administration, 10 HOUS. L. REV. 39, 46, 66 (2020) (describing the ADA generally and
advocating for use of the “methods of administration” claim); see also Colker, supra note
115, at 788 (discussing the ADA and its failure to respond to technological advances as
needed); cf. Claire Raj, The Promise and Peril of Using Disability Law as a Tool for School
Reform, 94 WASH. L. REV. 1831, 1833–38 (2019) (discussing the use of class actions under
Title II to extend the provisions of special education services to a population of children who,
by virtue of growing up in a specific community, have been exposed to Adverse Childhood
Experiences (ACEs) that impair their ability to learn).
189
For a history of the creation of Protection and Advocacy organizations (P&As) from the
government’s perspective, see Statement of Interest of the United States at 2–5, Disability
186
187
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However, both for those familiar with the ADA but not the process
by which research is conducted and those comfortable with the mechanisms
of research but not with the provisions of the ADA, it will create a framework
for working together to promote inclusion and harness available legal
protections against disability-based discrimination. Where needed, it will
identify some gaps in the ADA that will need to be addressed through
litigation or legislation. It concludes that the existing provisions of the ADA
as currently interpreted by the federal courts already provide a strong schema
for promoting inclusion of people living with disabilities in most of the
settings where research is conducted in the United States.
B. Legal Protection Against Disability-Based Discrimination
Discrimination based on disability is prohibited in the United States
by an interlocking network of federal and state laws190 similar to those
prohibiting discrimination based on race, religion, sex, or national origin. 191
Rights N.Y. v. N. Colonie Bd. of Educ., 2016 WL 1122055 (N.D.N.Y. 2016) (No. 1:14-cv774 (DNH/RFT)). For a history of advocacy organizations from a parent’s perspective, see
Melanie Perkins McLaughlin, Parent? Advocate? Or Both?: What Happens When We Put the
Burden on Parents to Push and Fight for Their Children With Special Needs?, HARV. ED.,
Summer 2018, at 25, https://www.gse.harvard.edu/sites/default/files/edmag/pdfs/2018-sum20.pdf [https://perma.cc/2NP8-2PXS]. See generally Protection and Advocacy for People
with Disabilities, NAT’L DISABILITY RTS. NETWORK, https://www.ndrn.org/ [https://
perma.cc/6NPD-JKJ4] (last visited Jan. 22, 2021) (describing how P&As and Client
Assistance Programs (CAPs) are “the nation’s largest providers of legal advocacy services for
people with disabilities.”).
190
All states must, at a minimum, comply with all the provisions of the ADA but are free to
add expanded protection. Many states have used their authority to extend the definition of a
qualified plaintiff beyond that of the ADA and deliberately extended protection to people
statutorily excluded. For a discussion of the relationship between state and federal laws
prohibiting disability-based discrimination, see Sara Wilson, State-Level Activism in the
Disability Context: Ensuring Protections for People with Disabilities Through American
Federalism and the Fourteenth Amendment Equal Protection Clause, 15 J. HEALTH &
BIOMEDICAL L. 173, 183–84 (2019). For an overview of state laws prohibiting disabilitybased discrimination, see STEPHEN A. ROSENBAUM, DISABILITY RIGHTS AND PUBLIC
ACCOMMODATIONS: STATE-BY-STATE 6–26 (2011) http://www.adasoutheast.org/publications/
ada/public_accommodations_disability_rights_state-by-state_Final.pdf [https://perma.cc/
H836-P4LA]. For a discussion of the distinct Titles of the ADA, see U.S Dep’t of Justice, A
Guide to Disability Rights Law, BRAINLINE, https://www.brainline.org/article/guidedisability-rights-laws (last visited June 17, 2020) [https://perma.cc/L6GB-H44U].
191
SARAH PARKER HARRIS, ROBERT GOULD, GLENN FUJIURA, ROBIN JONES, PATRICK OJOK
& AVERY OLMSTEAD, DEP’T OF DISABILITY & HUMAN DEV., SYSTEMATIC REVIEW PROJECT
YEAR 1: SCOPING REVIEW OF THE ADA 3 (2013), https://adata.org/sites/adata.org/files/files/
ADAKT_ScopingReview_TechnicalReport_2013.pdf [https://perma.cc/YEN4-ZPAA] (“The
Americans with Disabilities Act (ADA) is the cornerstone of US civil rights policy for people
with disabilities, and the primary legislative tool for ensuring their full and equal treatment
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Unlike the laws prohibiting other forms of discrimination, however, the ADA
imposes a positive obligation to promote “inclusion” of people with
disabilities.192 As Professor Jasmine Harris explains, “[p]rescriptively,
Congress designed the [ADA] to ensure that people with disabilities are not
denied access to employment, public services, and places of public
accommodations.”193 What can make disability discrimination law
challenging to apply is that within that general proscription against
discrimination, Congress has distinguished between the obligations of public
entities (federal, state, and city governments) and those of private entities.194
As a result, every case of disability-based discrimination must begin by
characterizing the status of the entity accused of discrimination and then
identifying the limits to which that particular covered entity must make
changes.195 While there are differences in the language of Title II and III, as
Professor Laura Rothstein explains, “[s]ubstantively, the two statutes provide
for both nondiscrimination and reasonable accommodations and require that
‘reasonable’ efforts must be in place to ensure access.”196 Both Titles excuse
entities from making “unduly burdensome” accommodations that
as citizens. The legislative intent of the ADA is to protect against discrimination while
simultaneously fostering social inclusion across all domains of public life.”). See generally
Kimani Paul-Emile, Blackness as Disability, 106 GEO. L.J. 293, 321 (2018) (“Persons
with disabilities have faced discrimination much like that experienced by black people.”).
192
In Olmstead v. L.C. ex rel. Zimring, Justice Ginsburg, writing for the Supreme Court,
upheld the Justice Department’s interpretation of the ADA as requiring “community-based
treatment for persons with mental disabilities when the State’s treatment professionals
determine that such placement is appropriate . . . and the placement can be reasonably
accommodated, taking into account the resources available to the State.” 527 U.S. 581, 607
(1999). See also Paul-Emile, supra note 191, at 327 n.211 (citing Mary C. Cerreto, Olmstead:
The Brown v. Board of Education for Disability Rights—Promises, Limits, and Issues,
3 LOY. J. PUB. INT. L. 47 (2001); Don Schanche, Jr., Georgia Lags in Responding
to Olmstead Decision, MACON TEL., Mar. 30, 2003, at A10 (“The Olmstead Decision has
become as significant for people with disabilities as ‘Brown v. Board of Education’ was for
the civil rights movement.”)).
193
Jasmine E. Harris, The Aesthetics of Disability, 119 COLUM. L. REV. 895, 896 (2019).
194
Nicole Flynn, Public and Private University Accessibility Law, CIELO24 (Jan. 6, 2016),
https://cielo24.com/2016/01/public-and-private-university-accessibility-law/ [https://perma.
cc/P4CA-CSAU] (explaining differences in how ADA accessibility requirements are applied
in public and private universities); The Tale of Two Titles: Title II and Title III; ADA
Compliance, BRAILLE WORKS (Apr. 19, 2016, 11:10 AM), https://brailleworks.com/title-iiand-title-iii-ada-compliance/ [https://perma.cc/ZX8Y-QXVW].
195
Frequently Asked Questions About Titles II and III of the ADA, U.S. DEP’T JUST.,
https://www.justice.gov/crt/frequently-asked-questions-about-titles-ii-and-iii-ada [https://perma.cc/
T2TG-KN8W] (“If a criterion screens out or tends to screen out individuals with disabilities,
it may only be used if necessary for the provision of the services.”).
196
Laura Rothstein, Forty Years of Disability Policy in Legal Education and the Legal
Profession: What Has Changed and What Are the New Issues?, 22 AM. U. J. GENDER, SOC.
POL’Y & L. 519, 528 (2014).
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“fundamentally alter the nature of the program” 197 or are “necessary for the
provision of services.”198 But Title II holds public entities to a higher standard
of proving that an accommodation which does not alter the nature of a
program or is not necessary to the provision of the services is nevertheless
unduly burdensome because it is “either financially or administratively”
unreasonable.199 Because the standards of proof under Title II and Title III
are different, the analysis of remedies for disability discrimination will
depend on first characterizing the entity conducting the research as either
public or private.200 Then, if private, remedies depend on whether or not in
conducting research it is serving as a place of public accommodation.
The current structure of federal laws prohibiting disability-based
discrimination represent a legislative process that began in 1968 with the Fair
Housing Act and took its current form with the passage of Section 504 of the
Rehabilitation Act of 1973 (Section 504), which prohibits disability-based
discrimination by “any program or activity” receiving federal financial
assistance.201 Today, the Rehabilitation Act has been joined by the four titles
of the Americans with Disabilities Act. 202 Taken together, they are intended
to combat the “various forms of discrimination” that “individuals with
disabilities continually encounter. 203 The four titles of the ADA provide
similar, although not identical, protections against disability discrimination
and also vary in terms of available remedies. 204 Additional protection is
Id.
Frequently Asked Questions About Titles II and III of the ADA, supra note 195.
199
Rothstein, supra note 196, at 528.
200
Donald J. Spero, Burdens of Proof of Reasonableness and Undue Harship Under Titles I, II
and III of the Americans With Disabilities Act, FLA. MEDIATION GRP. (Sept. 19, 2014, 11:33 AM),
http://www.2mediate.com/articles/spero/2002_Burdens_of_Proof_of_Reasonableness_and_Un
due_ Hardship_Americans_With_Disabilities_Act.html [https://perma.cc/UQ9S-D6CS].
201
29 U.S.C. § 794(a) (“No otherwise qualified individual with a disability in the United
States . . . shall, solely by reason of her or his disability, be excluded from the participation
in, be denied the benefits of, or be subjected to discrimination under any program or activity
receiving Federal financial assistance or under any program or activity conducted by any
Executive agency . . . .”).
202
For an overview of disability discrimination created by the office that enforces the ADA,
see Discrimination on the Basis of Disability, U.S. DEP’T HEALTH & HUM. SERVS.,
https://www.hhs.gov/civil-rights/for-individuals/disability/index.html [https://perma.cc/GYN9J4EQ] (last visited Jan. 23, 2021).
203
See 42 U.S.C. § 12101(a)(5) (outlining examples of these various forms of discrimination,
“including outright intentional exclusion, the discriminatory effects of architectural,
transportation, and communication barriers, overprotective rules and policies, failure to
make modifications to existing facilities and practices, exclusionary qualification standards
and criteria, segregation, and relegation to lesser services, programs, activities, benefits, jobs,
or other opportunities”).
204
See Ruth Colker, ADA Title III: A Fragile Compromise, 21 BERKELEY J. EMP. & LAB. L.
377, 377–78 (2000) (“[T]he broad coverage of ADA Title III came at a price—as part of a
197
198
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provided by federal laws that protect against discrimination based on
genetics.205
The ADA was passed in an atmosphere of great hope. Its stated
purpose is to “to provide a clear and comprehensive national mandate for the
elimination of discrimination against individuals with disabilities.”206
President George H.W. Bush said at the ADA signing ceremony, “[w]ith
today's signing of the landmark Americans with Disabilities Act, every man,
woman, and child with a disability can now pass through once-closed doors
into a bright new era of equality, independence, and freedom.”207
The Justice Department, which enforces ADA violations, has been
steadfast in its position that there should be no disability-based discrimination
in health care. Settling a case with a physician who refused to treat a patient
with HIV, the Justice Department announced: “Discrimination by those in
the medical profession breaks a trust critical to ensuring access to appropriate
treatment for all.”208 This prohibition applies not just to all publicly run or
funded entities or institutions but extends to any entity providing healthcare
to the public. Title III directly identifies as covered entities the “professional
office of a health care provider, hospital, or other service establishment,”
whether it is public or not.209
‘fragile compromise.’ In return for a broad list of covered entities, civil rights advocates
agreed to a limited set of remedies under ADA Title III. When private parties bring suit
under ADA Title III, they are only able to obtain injunctive relief and are not able to obtain
monetary damages.” (internal citation omitted)). For an overview of the challenges of
enforcing the ADA because of the difference in available remedies see Harris, supra note 12,
at 481 (“Yet the ADA’s remedial structure in many ways creates “rights without remedies”
with respect to public entities by denying plaintiffs monetary damages. Weak enforcement
of Title II and the lack of a threat of damages beyond cases of “intentional discrimination,”
coupled with Title III’s sole remedy of injunctive relief, continue to limit the ADA’s deterrent
value and promise of integration.” (internal citations omitted)).
205
While beyond the scope of this article, the Genetic Information Nondiscrimination Act of
2008 extended some of the ADA’s protection to people who are discriminated against based
on genetic information. For a comparison of the protections of the ADA and GINA, see Mark
A. Rothstein, GINA, the ADA, and Genetic Discrimination in Employment, 36 J.L. MED.
ETHICS 837 (2008).
206
42 U.S.C. § 12101(b)(1).
207
Remarks on Signing the Americans with Disabilities Act of 1990, 1990 PUB. PAPERS 1065
(July 26, 1990).
208
Press Release, U.S. Dep’t. of Just., Justice Department Settles with Indiana Doctor
Over Discrimination Against an Individual with HIV, No. 16-419 (Apr. 7, 2016).
209
42 U.S.C. § 12181(7)(F); 28 C.F.R. § 36 app. C, at 952 (2019) (explaining that the office
of a health care provider may qualify as a covered entity even if it is located in a private
home); see also Elizabeth Pendo, Disability, Equipment Barriers, and Women's Health:
Using the ADA to Provide Meaningful Access, 2 ST. LOUIS U. J. HEALTH L. & POL'Y 15, 33
(2008) (“Title III of the ADA prohibits discrimination in privately-owned places of public
accommodation, and provides that ‘[n]o individual shall be discriminated against on the basis
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But well beyond healthcare, the ADA’s prohibition against disabilitybased discrimination reaches into all aspects of daily life prohibiting
discrimination in housing, education, healthcare, and transportation. 210 It
prohibits discriminatory behavior by public and private entities and imposes
affirmative obligations to create an accessible environment. 211
C. Making a Prima Facie Case for Discrimination Under the ADA
All the statutes discussed in this article providing protection from
disability-based discrimination require potential plaintiffs to first prove that
they meet the legal criteria for bringing suit. Relief under Title II of the ADA
requires that a plaintiff prove that she is a qualified person with a disability 212
and under Title III that she is a person with a disability.213 Many state laws
of disability in the full and equal enjoyment of the goods, services, facilities, privileges,
advantages, or accommodations of any place of public accommodation by any person who
owns, leases (or leases to), or operates a place of public accommodation.’ ‘Public
accommodation’ includes a wide range of commercial facilities and establishments, and
explicitly includes the private offices of health care providers and private hospitals.”
(footnotes omitted)).
210
See Laura F. Rothstein, Teaching Disability Law, 48 J. LEGAL EDUC. 297, 299 (1998)
(“The ADA . . . greatly extended coverage of the private sector, prohibiting discrimination by
most private employers, by most private programs of public accommodation, and by state and
local governmental entities (including those not receiving federal funds).” citations omitted)).
211
Id.
212
Bragdon v. Abbott, 524 U.S. 624, 632 (1998). Because the definition of a qualified
plaintiff, disabling conditions, and major life activities were expanded by the ADA
Amendments Act of 2008, 42 U.S.C. § 12102(2)(A), it is important that only cases after that
date are used as precedents on this issue. It is also important to note that while the standards
for inclusion are not meant to be definitive, there are very specific standards for exclusion.
See 29 U.S.C. § 705(20)(F) (“‘[I]ndividual with a disability’ does not include an individual
on the basis of—(i) transvestism, transsexualism, pedophilia, exhibitionism, voyeurism,
gender identity disorders not resulting from physical impairments, or other sexual behavior
disorders; (ii) compulsive gambling, kleptomania, or pyromania; or (iii) psychoactive
substance use disorders resulting from current illegal use of drugs.”); 42 U.S.C.§ 12211(b)
(mirroring the exclusions listed under 29 U.S.C. § 705(20)(F)). For an overview of how
plaintiffs qualify under all provisions of the ADA, see ADA Amendments Act of 2008
(ADAAA), Pub. L. No. 110-325, § 2(b)(1), 122 Stat. 3553, 3554 (2008) (codified at 42
U.S.C. § 12102).
213
42 U.S.C. § 12133; 28 C.F.R. § 36.104 (2019); see also U.S. Dep’t of Just., ADA Title III
Technical Assistance Manual: Covering Public Accommodations and Commercial Facilities,
ADA.GOV, https://www.ada.gov/taman3.html [https://perma.cc/24LY-UVD6] (last visited
Jan. 24, 2021) (“Title III protects three categories of individuals with disabilities: 1)
Individuals who have a physical or mental impairment that substantially limits one or more
major life activities; 2) Individuals who have a record of a physical or mental impairment
that substantially limited one or more of the individual’s major life activities; and 3)
Individuals who are regarded as having such an impairment, whether they have the
impairment or not.”).
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prohibiting disability discrimination expand the definition of disability, thereby
widening the population of plaintiffs in those jurisdictions who can seek
protection.214 This analysis assumes a plaintiff who meets the threshold status
requirement of the legal provision under which they are bringing action.
D. Proving Discrimination
Having proved that the plaintiff is qualified, and the entity covered,
the next task is proving that they have experienced discrimination. They do
not have to prove that the discrimination was deliberate or even that
discrimination was of a type against which Congress intended to protect.215
Title II’s provisions related to actions of the federal government, are intended
not only to “protect disabled persons from discrimination arising out of . . .
discriminatory animus,” but also to protect from “thoughtlessness,”
“indifference,” or “benign neglect.”216 Moreover, Title II of the ADA
provides that “[a] public entity, in providing any aid, benefit, or service, may
not . . . utilize criteria or methods of administration . . . [t]hat have the effect
of subjecting qualified individuals with disabilities to discrimination on the
basis of disability.”217
A study that explicitly excludes people living with a disability from
participation would be a paradigmatic example of active discrimination. But
it is also possible to prove discrimination without evidence of an explicit ban.
Title II of the ADA prohibits public entities from “utiliz[ing] criteria or
methods of administration”218 that “deny individuals with disabilities access to
the public entity’s services, programs, and activities.”219 This so called “methods
of administration” provision extends broad protection for practices of an entity
that serve to discriminate or which have a disparate impact on participation.

See Eve Hill & Sheila Khan-Variba, Challenging Barriers, L.A. LAW., Nov. 2005, at 31
(reviewing California’s statutes prohibiting discrimination on the basis of disability); 42
U.S.C. § 12102(2) (providing federal definition of disability and related terms); 28 C.F.R. §
36.105 (2019) (same).
215
See Bostock v. Clayton Cty., 140 S.Ct. 1731, 1751 (2020) (citing Pa. Dep’t of Corrs. V.
Yeskey, 524 U.S. 206, 212 (1998)) (noting that in the presence of “unambiguous statutory
text” prohibiting discrimination, “whether a specific application was anticipated by Congress
‘is irrelevant’”).
216
Crowder v. Kitagawa, 81 F.3d 1480, 1484 (9th Cir. 1996) (quoting Alexander v. Choate,
469 U.S. 287, 295 (1985).
217
28 C.F.R. § 35.130(b)(1)–(3) (2019).
218
Id. § 35.130(b)(3).
219
Id. § 35 app. B, at 709.
214

Vol. 6:3]

Lifting the Barriers

537

In broad terms, this means proof that a covered entity220 has treated
them differently from the way it treats people who are not living with a
disability. Unless the plaintiff seeks to recover money damages, she does not
have to prove that the discrimination was intentional, just that it was a result
of the covered entity’s actions. But if the plaintiff proves intentional
discrimination, the burden shifts to the defendant.
There are three major legal theories available to a qualified plaintiff
for proving discrimination.221 They are that a covered entity’s actions were
intentional disparate treatment,222 they had a disparate impact on the plaintiff
because of her disability,223 or the covered entity failed to provide reasonable
The obligations of a covered entity are broad. As the Office of Civil Rights explains:
Covered entities must not, on the basis of disability:
• Exclude a person with a disability from a program or activity;
• Deny a person with a disability the benefits of a program or activity;
• Afford a person with a disability an opportunity to participate in
or benefit from a benefit or service that is not equal to what is
afforded others;
• Provide a benefit or service to a person with a disability that is
not as effective as what is provided others;
• Provide different or separate benefits or services to a person with
a disability unless necessary to provide benefits or services that
are as effective as what is provided others;
• Apply eligibility criteria that tend to screen out persons with
disabilities unless necessary for the provision of the service,
program or activity.
Covered entities must:
• Provide services and programs in the most integrated setting
appropriate to the needs of the qualified individual with a disability;
• Ensure that programs, services, activities, and facilities are accessible;
• Make reasonable modifications in their policies, practices, and
procedures to avoid discrimination on the basis of disability,
unless it would result in a fundamental alteration of the program;
• Provide auxiliary aids to persons with disabilities, at no additional
cost, where necessary to afford an equal opportunity to participate
in or benefit from a program or activity . . . .
Discrimination on the Basis of Disability, supra note 202.
221
See Davis v. Shah, 821 F.3d 231, 259 (2d Cir. 2016) (quoting Fulton v. Goord, 591 F.3d 37, 43
(2d Cir. 2009)) (“To state a prima facie claim under either provision, a plaintiff must establish ‘(1)
that she is a qualified individual with a disability; (2) that she was excluded from participation in
a public entity's services, programs or activities or was otherwise discriminated against by a public
entity; and (3) that such exclusion or discrimination was due to her disability.’”).
222
See, e.g., Sch. Bd. Of Nassau Cnty. v. Arline, 480 U.S. 273, 283 n.9 (1987) (noting
Representative Vanik’s view that the Rehabilitation Act prohibits exclusion of a child with
cerebral palsy from the classroom of a public school because the child “produced a
nauseating effect” on his peers).
223
See, e.g., Prewitt v. U.S. Postal Serv., 662 F.2d 292, 306 (5th Cir. Unit A Nov. 1981) ( “In
220
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accommodation.224 All three could be the basis for a claim based on exclusion
from research. Courts have consistently found that plaintiffs need not prove
individual animus or “obviously exclusionary conduct.”225 Instead,
discrimination can be proved by deliberate indifference.226
1. Disparate treatment: deliberate discrimination
Under the ADA, the term “disparate treatment”—common to many
federal anti-discrimination laws—means treatment based on deliberate
discrimination rather than an accidental phenomena outside the entity’s
control which it had no duty to prevent. 227 In Prewitt v. U.S. Postal Service,
the U.S. Court of Appeals for the Fifth Circuit identified actions taken based
on “social bias” regarding persons with disabilities as “intentional
discrimination” which resulted in treating people with disabilities differently
from people in similar circumstances without disabilities. 228 At this stage of
establishing a prima facie case, it is the treatment that matters, not the reason
for it. So, for example, if a study design does not explicitly exclude people
with disabilities but is designed in a way that prevents them from
participating, such as requiring the ability to hold a pencil or stand for a chest
x-ray,229 plaintiffs can argue that otherwise neutral provisions can have a
disparate impact on people with disabilities because it prevents them from
participating.230 Both Title II and Title III mandate that covered entities must
affirmatively identify barriers to accessibility and take steps “as may be
necessary to ensure that no individual with a disability is excluded, denied
the discriminatory impact context . . . [a]ll a plaintiff need prove to establish a prima facie
case is that the challenged standard disparately disadvantages the protected group of which
he is a member . . . .”).
224
42 U.S.C. § 12112(b)(5); see also, e.g., Prewitt, 662 F.2d at 305 (finding that plaintiff may
be entitled to relief if the postal service refused to hire him “even though he could have
performed the essentials of the job if afforded reasonable accommodation”); Crowder v.
Kitagawa, 81 F.3d 1480, 1484 (9th Cir. 1996) (finding that the state’s animal quarantine law
that disproportionately affected people with disabilities violated the ADA).
225
See Chapman v. Pier 1 Imps., 631 F.3d 939, 945 (9th Cir. 2011) (“The concept of
‘discrimination’ under the ADA does not extend only to obviously exclusionary conduct—
such as a sign stating that persons with disabilities are unwelcome or an obstacle course
leading to a store’s entrance.”).
226
Alexander v. Choate, 469 U.S. 287, 295 (1985) (“Discrimination against the handicapped
was perceived by Congress to be most often the product, not of invidious animus, but rather
of thoughtlessness and indifference—of benign neglect.”).
227
42 U.S.C. § 12112.
228
Prewitt, 662 F.2d at 305 n.19.
229
For examples of these kinds of exclusionary designs, see Rios et al., supra note 37.
230
See, e.g., Crowder v. Kitagawa, 81 F.3d 1480, 1484 (9th Cir. 1996) (finding that a sixmonth quarantine of all dogs had a disparate impact on individuals with disabilities who
needed access to their service animals)

Vol. 6:3]

Lifting the Barriers

539

services, segregated or otherwise treated differently than other individuals
because of the absence of auxiliary aids and services.”231
If a plaintiff proves discrimination, then the burden shifts to the entity
to show why they should not make the changes necessary to change whatever
is causing the discrimination. 232
2. Justifying inaccessible research
Finally, if a qualified plaintiff can prove disability-based
discrimination by a covered entity, the final issue is the entity’s legal
obligation to make research accessible. 233 Both Title II and III require
covered entities to make reasonable efforts. 234 The ADA identifies three
major actions which covered entities must do in order to make reasonable
accommodations that assure access for people with disabilities. They are the
“modifications to rules, polices, or practices;” 235 “the removal of . . .
barrier[s];”236 and the provision of “auxiliary aids and services.”237 It is,
therefore, likely that most research will take place in an entity that is either
covered by Title II because of how it is funded or Title III because it provides
healthcare. The extent of changes that entities conducting research have to
make in order to include people with disabilities is defined differently under
Title II and Title III. A Title II covered entity must make “reasonable
modifications” that would accommodate the plaintiff’s disability unless
231

42 U.S.C. § 12182(b)(2)(A)(iii) (emphasis added).
See Warden, supra note 188, at 53 (arguing for greater use of the methods of
administration clause as a stand-alone cause of action to “address animus, deliberate
indifference, thoughtlessness, apathy, and even benign neglect” if the result is disabilitybased discrimination).
233
See generally Rios et al., supra note 37 (outlining their approach to making research
accessible modeled on universal design, accommodations, and modifications).
234
See Rothstein, supra note 196, at 528 (“Substantively, the two statutes provide for both
nondiscrimination and reasonable accommodations and require that ‘reasonable’ efforts must
be in place to ensure access. Accommodations that are unduly burdensome, either financially
or administratively, or that fundamentally alter the nature of the program, are not required.”).
235
42 U.S.C. § 12131(2) (“The term ‘qualified individual with a disability’ means an
individual with a disability who, with or without reasonable modifications . . . meets the
essential eligibility requirements for the receipt of services or the participation in programs
or activities provided by a public entity.”).
236
42 U.S.C. § 12182(b)(2)(A)(v); see AMERICANS WITH DISABILITIES: PRACTICE AND
COMPLIANCE MANUAL, § 4:106 (database updated Feb. 2021) (“The obligation to engage in
readily achievable barrier removal under Title III . . . is a continuing one, and it is
discriminatory for a public accommodation to fail to take reasonable measures to remove
architectural and other barriers to accessibility.”); id. § 1:264 (“[A] plaintiff’s failure to
expressly ‘request’ an accommodation is not fatal to a claim where the defendant otherwise
had knowledge of an individual’s disability and needs but took no action.”).
237
28 C.F.R. § 35.160(b)(1) (2019); see id. § 36.303(b)(1)–(4) (defining auxiliary aids and
services under Title III).
232
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doing so would “‘fundamentally alter’ the services or accommodations being
offered.”238 A Title III covered entity must also make “reasonable
modifications” that would accommodate plaintiff’s disability, but only if
“such removal is ‘readily achievable’” without fundamentally altering public
accommodation’s nature.239
Looking ahead, plaintiffs seeking these accommodations are likely to
find that their most significant barrier is the existence of rigid exclusion criteria
that arbitrarily exclude people with disabilities without proper consideration of
whether the disability would actually impact participation.240
E. How do Research Sites or Sponsors Qualify as “Covered Entities”?
Once a plaintiff is found to be eligible to invoke the ADA’s
protection, the next issue is whether she can meet her burden of proving that
she has experienced discrimination by a covered entity. Below is a brief
explanation of proving discrimination under the ADA, followed by scenarios,
each of which matches provisions of the ADA applicable to the entity most
likely to conduct related research studies.
1. Research conducted by the federal government: a vaccine trial at
NIH
The Federal Government conducts research studies directly through a
network of entities connected with different agencies and entities. 241
Research conducted by a public entity such as a government agency
or a public school, university, or hospital is subject to Section 504 of the
Rehabilitation Act and Title II242 of the Americans with Disabilities Act. 243
238

See Spector v. Norwegian Cruise Line Ltd., 545 U.S. 119, 128–29, 135–36 (2005)
(holding that foreign cruise ships in U.S. waters were subject to Title III of the ADA,
mandating that specific accommodations sought by the plaintiffs be made because they were
“readily achievable,” did not pose “a significant risk to health or safety of others,” and were
“easily accomplishable and able to be carried out without much difficulty or expense”.”).
239
Id. at 126–27.
240
For examples of these kinds of exclusionary designs see Rios et al., supra note 37, at 2138.
241
Finding a Clinical Trial, NAT’L INSTS. HEALTH (Nov. 6, 2018), https://www.nih.gov/
health-information/nih-clinical-research-trials-you/finding-clinical-trial [https://perma.cc/
5D5U-7X4D].
242
Title II prohibits any public entity from discriminating against “qualified” persons with
disabilities in the provision or operation of public services, programs, or activities. 42 U.S.C.
§§ 12131–12134.
243
Warden, supra note 188, at 46 (citing Windham v. Harris Cty., 875 F.3d 229, 235 (5th Cir.
2017)) (“Generally, in order to win any case under this provision, plaintiffs must prove a
prima facie case: (1) that he or she is an otherwise qualified individual with a disability (2)
that they have been subject to discrimination by a public entity and (3) that such
discrimination was by reason of disability.”).
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Section 504 provides that “no qualified individual with a disability shall, by
reason of such disability, be excluded from participation in or be denied the
benefits of the services, programs, or activities of a public entity, or be
subjected to discrimination by any such entity.” 244 This is true whether the
study involves the federal government directly, as the hundreds of clinical
trials conducted by the NIH in its facilities in Bethesda, Maryland, 245 or by a
state chartered public university, academic medical center, or hospital.246 The
Act defines the term “public entity” to include state and local governments,
as well as their agencies and instrumentalities.247
2. Research funded by the federal government
While the amount of research conducted directly by the federal
government is fairly small, the amount of research funded by the federal
government is vast.248 These studies extend across a broad array of fields
42 U.S.C. § 12132.
Finding a Clinical Trial, supra note 241 (“The NIH maintains an online database of
clinical research studies taking place at its Clinical Center, which is located on the NIH
campus in Bethesda, Maryland.”).
246
For an overview of the structure of higher education in the United States see U.S. Dep’t
of State, Understanding U.S. Higher Education, EDUC. USA, https://educationusa.state.gov/
foreign-institutions-and-governments/understanding-us-higher-education [https://perma.cc/
DC6R-3F3C] (last visited Feb. 27, 2021). In the United States a “public university” refers to
an institution of higher education chartered directly by the federal, state, or city government.
See Gary Moss, What Does it Mean to be a Public University?, U.N.C. CHAPEL HILL:
AROUND CAMPUS (Apr. 18, 2018) https://www.unc.edu/posts/2018/04/18/mean-publicuniversity/ [https://perma.cc/H4ZB-NPWC]. The first public university in the United States
was chartered by the State of North Carolina in 1789 with legislation stating that “it is the
indispensable duty of every Legislature to consult the happiness of a rising generation and
endeavor to fit them for an honourable discharge of the social duties of life, by paying the
strictest attention to their education.” Id.
247
42 U.S.C. § 12131(1).
248
For example, the National Science Foundation, “funds research and education in
most fields of science and engineering. It does this through grants, and cooperative
agreements to more than 2,000 colleges, universities, K-12 school systems, businesses,
informal science organizations and other research organizations throughout the United
States.” About Funding, NAT’L SCI. FOUND., https://www.nsf.gov/funding/aboutfunding.jsp
[https://perma.cc/M3UF-BBY4] (last visited Feb. 27, 2021); see also NSF By Account, NAT’L
SCI.
FOUND.,
https://dellweb.bfa.nsf.gov/NSFFundingbyAccountConstantDollars.pdf
[https:// perma.cc/9KFJ-KCM7] (last visited Jan. 23, 2021) (stating that for Fiscal Year 2020,
the National Science Foundation was allocated federal funding of $8,278,330,000);
Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC),
NAT’L INSTS. HEALTH: REPORT (Feb. 24, 2020), https://report.nih.gov/funding/categoricalspending [https://perma.cc/5HZ7-QCFQ] (outlining funding amounts allocated to research
studies by condition or disease category); Budget, NAT’L INSTS. HEALTH, https://www.nih.gov/
about-nih/what-we-do/budget [https://perma.cc/F8PX-9NWV] (last visited Feb. 27, 2021)
(“NIH invests about $41.7 billion annually in medical research for the American people.”).
244
245
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ranging from education249 to social science to medicine. 250 It would be
difficult to construct an argument exempting research funded by the federal
government from federal laws preventing disability discrimination. By
prohibiting disability-based discrimination by any program or activity
receiving Federal financial assistance, Title II of the Americans with
Disabilities Act applies to anything a public entity does.251
3. Exclusion from a clinical trial not directly funded by the federal
government
Therefore, even research sponsored by a private entity which does not
provide health care to the public must comply with the ADA if it occurs as
part of the care a patient is receiving. 252
While different entities use different definitions, this article will use
the term “clinical trials” to encompass all biomedical research that involves
an intervention which must be conducted under the supervision of a licensed
physician.253 A biomedical research study that takes place in an entity,
For an example of a research study involving humans but not clinical medicine, see For
Worriers, Expressive Writing Cools Brain on Stressful Tasks, MSU TODAY (Sept. 14, 2017),
http://msutoday.msu.edu/news/2017/for-worriers-expressive-writing-cools-brain-on-stressfultasks/ [https://perma.cc/P76F-64KN].
250
See CLINICALTRIALS.GOV [https://perma.cc/4PPM-9LGK] (last visited Jan. 23, 2021)
(“ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted
around the world.”).
251
42 U.S.C. § 12131(1) (extending protections of Rehabilitation Act to all public entities);
28 C.F.R. § 35, app. B (2019) (providing guidance on Title II application to matters within
the scope of the Department of Transportation).
252
Raymond T. Foster, Sr., Academic Medical Centers, Private Industry, and Clinical Trials:
How Do We Achieve Fairness, Objectivity, and Balance?, 18 INT’L UROGYNECOLOGY J. 233,
235 (2007) (“With shrinking public money to support clinical research, we will have
increased reliance on private sponsorship in the future. Our challenge is to establish a system
of checks and balances that protects the welfare of our patients, allows us to continue to
conduct quality research, and rewards private companies that make products that improve the
health of our patients.”).
253
As defined by the National Institutes of Health, “[c]linical research is medical research
involving people.” “Clinical trials” are “research studies performed in people that are aimed
at evaluating a medical, surgical, or behavioral intervention. They are the primary way that
researchers find out if a new treatment, like a new drug or diet or medical device (for
example, a pacemaker) is safe and effective.” What Are Clinical Trials and Studies?, NAT’L
INST. ON AGING, https://www.nia.nih.gov/health/what-are-clinical-trials-and-studies
[https://perma.cc/8S79-CBRK] (last visited Jan. 23, 2021). The FDA’s definition is
somewhat different, “[c]linical trials are voluntary human research studies designed to
answer specific questions about the safety and effectiveness of drugs, vaccines, devices, and
other therapies—or to study new ways of using existing treatments.” FDA Encourages More
Participation, Diversity in Clinical Trials, FDA (Jan. 16, 2018), https://www.fda.gov/
consumers/consumer-updates/fda-encourages-more-participation-diversity-clinical-trials
[https://perma.cc/G5E3-KRJE].
249
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whether public or private, which provides health care to the public must make
“services fully available to individuals with disabilities.”254 There are four
overlapping federal laws that directly prohibit disability-based discrimination
by individuals and entities which provide healthcare. The first three, Section
504 of the Rehabilitation Act and Sections II and III of the ADA, apply to the
entity as a whole, not specifically to the delivery of healthcare. The fourth,
Section 1557 of the Affordable Care Act, is specific to the provision of
healthcare. Because there has not, as yet, been a reported case applying any
of these provisions to exclusion from a research study, the scenarios below
match typical research settings to the most plausible relevant legal provisions
with the understanding that more than one can apply depending on a future
court’s characterization of the activity or entity involved.
One of the most interesting issues that will arise in seeking inclusion
in a clinical trial is the fluid legal boundary between “health care” and
“research” when both are being provided by publicly funded entities.
Almost all colleges, universities, and academic medical centers in the
United States, whether public or private, receive some federal funding which, in
turn, requires them to follow federal law.255 These studies would most likely be
clinical trials intended to gather information needed to seek FDA approval to
market a new drug, device, or biologic.256 The paradigm examples are the
vaccine trials currently being conducted by companies like Moderna that are
unaffiliated with any universities or academic medical centers and which involve
healthy individuals who are not seeking or receiving healthcare.
U.S. DEP’T OF JUST. & U.S. DEP’T OF HEALTH & HUM. SERVS., ACCESS TO MEDICAL CARE FOR
INDIVIDUALS WITH MOBILITY DISABILITIES 1 (2010), https://www.hhs.gov/sites/default/files/
ocr/civilrights/understanding/disability/adamobilityimpairmentsgudiance.pdf [https://perma.cc/
WN6B-T788].
255
See Dean Clancy, A List of Colleges That Don’t Take Federal Money, DEAN CLANCY
(Aug. 10, 2020), https://deanclancy.com/a-list-of-colleges-that-dont-take-federal-money
[https://perma.cc/U572-VKZK] (listing eighteen “colleges in the United States [that], in
order to preserve their liberty and independence, do not accept grants from the federal
government or participate in any federal financial-aid or student-loan program”); Ibby
Caputo & Jon Marcus, The Controversial Reason Some Religious Colleges Forgo Federal
Funding, ATLANTIC (July 7, 2016) https://www.theatlantic.com/education/archive/ 2016/07/
the-controversial-reason-some-religious-colleges-forgo-federal-funding/490253
[https://perma.cc/Z2HM-DGN9] (“Thirty-eight religiously affiliated institutions have
received exemptions from Title IX, according to a list released by the Education
Department.”); Lydia Wheeler, DeVos: All Schools That Receive Federal Funds Must
Follow Federal Law, THE HILL (June 6, 2017, 11:07 AM) https://thehill.com/reg
ulation/administration/336517-devos-all-school-that-receive-federal-funds-must-follow-fed
eral-law [https://perma.cc/NQ93-7SGP] (reporting Secretary DeVos’ answer to questions
from Senator Patty Murray about the requirement that schools receiving federal funding
follow federal law).
256
It is difficult to find any official list of colleges that do not take federal funding, although
the general agreement is that it is very small.
254
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In guidance directed specifically to physicians, the Justice
Department wrote that: “The ADA requires access to medical care services
and the facilities where the services are provided. Private hospitals or medical
offices are covered by Title III of the ADA as places of public
accommodation.”257 Public hospitals must make their “services available
through alternative methods . . . . Under Title II, a public entity must ensure
that its program as a whole is accessible.”258
A hospital, clinic, or doctor’s office, even if privately owned, is a
place of public accommodation. 259 A person who is “subject[] to
discrimination” or “who has reasonable grounds for believing that such
person is about to be subjected to discrimination” on the basis of disability
may bring a private right of action to seek injunctive relief under Title III. 260
Certainly these organizations are bound by the provisions of Title I of the
ADA, which prohibits discrimination in employment. There is nothing about
a pharmaceutical company or a biomedical research organization operating
in the United States that would permit them to discriminate based on
disability in the studies they conduct.
Both the type of discrimination and the nature of the entity charged
with discrimination determine which Title of the ADA to apply. The activities
that make up “research” and nature of the entities where research is conducted
make the Rehabilitation Act, Title II 261, and Title III the most likely sources
of protection.
4. Research conducted by or at a private entity which receives federal
funding: the case of Dolly Parton
Another scenario where an individual might seek admission to a
clinical trial is one where a privately funded study is conducted at an
institution which receives federal funding. 262
A recent news item revealing that the Dolly Parton Foundation had
contributed $1,000,000 to COVID-19 research conducted at Vanderbilt
257

ACCESS TO MEDICAL CARE, supra note 254, at 1.
Id.
259
28 C.F.R. § 36.104 (2019).
260
28 C.F.R. § 36.501(a) (2019). Title III of the ADA, which, among other things, requires
an entity operating “public accommodations” to make “reasonable modifications” in its
policies “when . . . necessary to afford such . . . accommodations to individuals with
disabilities, unless the entity can demonstrate that making such modifications would
fundamentally alter the nature of such . . . accommodations,” 42 U.S.C. § 12182(b)(2)(A)(ii).
261
42 U.S.C. §§ 12131–34.
262
“No otherwise qualified individual with a disability . . . shall, solely by reason of his or
her disability, be excluded from the participation in, be denied the benefits of, or be subjected
to discrimination under any program or activity receiving Federal financial assistance.” 29
U.S.C. § 794(a).
258
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University illustrates the growing role of private foundations in funding
biomedical research.263 But for purposes of the ADA, the relevant factor is
the place where the research is conducted, not the funding source. Nor is it
relevant that the hospital or university, here Vanderbilt, is private. 264 Title III
of the ADA prohibits disability-based discrimination by private, commercial
entities which meet the criteria for designation as places of “public
accommodation” or the legal criteria for being so considered. 265 This includes
private hospitals, universities, and research institutes.266
All universities that receives federal research funding and all medical
facilities that provides healthcare to the public will still be covered entities
under the ADA, regardless of who funds the research.
5. Exclusion from biomedical research in a place that does not receive
federal funding but does provide health care to the public
If the medical facility is public, then it comes under the jurisdiction
of the Rehab Act and Title II. 267 This includes doctors’ offices located in
private homes.268 Title III of the ADA defines “[h]ospitals, clinics, and
Dave Paulson, Dolly Parton Says She’ll Donate $1 Million for Coronavirus Research at
Vanderbilt, TENNESSEAN (Apr. 1, 2020, 11:53 AM), https://www.tennessean.com/story/enter
tainment/music/2020/04/01/dolly-parton-donating-1-million-coronavirus-research-vander
bilt/5104191002/ [https://perma.cc/G9M5-YHJ8]; Maria Cramer, Dolly Parton: Singer,
Songwriter, Pandemic Savior?, N.Y. TIMES (Nov. 17, 2020), https://www.nytimes.com/2020/
11/17/arts/music/dolly-parton-moderna-virus.html [https://perma.cc/HPD5-5VQX]; Allie
Clouse, Dolly Parton Helped Fund 95% Effective Moderna COVID-19 Vaccine That Could
End Pandemic, TENNESSEAN (Nov. 17, 2020, 2:47 PM), https://www.tennessean.com/
story/entertainment/2020/11/17/dolly-parton-vaccine-funding-moderna-covid-19/6322836002
[https://perma.cc/PG4M-324G].
264
Title III provides that “[n]o individual shall be discriminated against on the basis of a
disability in the full and equal enjoyment of the . . . privileges . . . of any place of public
accommodation.” 42 U.S.C. § 12182(a). See Tennessee v. Lane, 541 U.S. 509, 516–17 (2004)
(describing the functions of Titles I, II, and III of the ADA).
265
Title III uses the word “accommodation” in two different ways. The first, “[p]ublic
accommodations,” is a description of the characteristics of a private entity that nevertheless
must offer the same kind of access to people living with disabilities as a public entity. Private
entities which offer public accommodations may not “discriminate[] on the basis of disability
in the full and equal enjoyment of the goods, services, facilities, privileges, advantages, or
accommodations of any place of public accommodation.” 42 U.S.C. §12182(a).
266
Id. § 12181.
267
Id. §§ 12131–12134.
268
Id. § 12181(7)(F); 28 C.F.R. § 36 app., at 696 (2019) (providing that the office of a health
care provider may be included even if it is located in a private home, to the extent it is a
portion of the home); see also Pendo, supra note 209, at 33 (“Title III of the ADA prohibits
discrimination in privately-owned places of public accommodation, and provides that ‘[n]o
individual shall be discriminated against on the basis of disability in the full and equal
263
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doctors’ offices” as places of “public accommodation” because they provide
healthcare services to the public. 269 If a private entity meets the criteria for
being designated a public entity, then it must provide the accommodations to
give people with disabilities the same access as people without disabilities. 270
F. Obligations to Eliminate Barriers to Access under Title III of the ADA
1. Biomedical research studies conducted by private entities who do
not provide healthcare
The scenarios above primarily concerned research studies that were
covered under Title II as public271 or Title III as places of public
accommodation, including providers of health care to the public, 272 but there
are some studies that take place in private facilities that are either in-house to
the drug developer or stand-alone Clinical Research Centers.273 The issue
with these entities is whether they would be classified as places of public
accommodation. In order to sell a newly developed drug in the United States,
a drug company (“the Sponsor”) must obtain the approval of the Food and
Drug Administration (“FDA”) which is charged by Congress to certify that

enjoyment of the goods, services, facilities, privileges, advantages, or accommodations of
any place of public accommodation by any person who owns, leases (or leases to), or
operates a place of public accommodation.’ ‘Public accommodation’ includes a wide range
of commercial facilities and establishments, and explicitly includes the private offices of
health care providers and private hospitals.” (footnotes omitted)).
269
28 C.F.R. § 36.505 (2019).
270
Baughman v. Walt Disney World Co., 685 F.3d 1131, 1135 (9th Cir. 2012) (“Public
accommodations must start by considering how their facilities are used by non-disabled
guests and then take reasonable steps to provide disabled guests with a like experience.”).
271
See Manhattan Cmty. Access Corp. v. Halleck, 139 S. Ct. 1921, 1932 (2019) (“[B]eing
regulated by the State does not make one a state actor.”). Nor are private universities state
actors simply because they are subject to state regulation. See Klunder v. Brown Univ., 778
F.3d 24, 33 (2015) (citing Krohn v. Harvard L. Sch., 552 F.2d 21, 24 (1st Cir. 1977) (“[T]he
receipt of state financial assistance, the regulation by a public accreditation council, and the
authority of that council to oversee disciplinary procedures ‘were insufficient attributes of
government involvement to render the university’s disciplinary proceedings ‘state action’
for section 1983 purposes”)).
272
There is a dispute in the Circuits about how far to extend the definition of “place.”
Compare, e.g., Magee v. Coca-Cola Refreshments USA, Inc., 833 F.3d 530, 534, 534 n.23
(5th Cir. 2016) (holding that a Coca-Cola machine is not a “place” of public
accommodation), with, e.g., Morgan v. Joint Admin. Bd., 268 F.3d 456, 459 (7th Cir. 2001)
(holding that “public accommodation” under Title III was not limited to a “physical site” and
therefore could extend to the terms of a retirement plan).
273
For a description of the purposes of a phase one trial, see Amit Mahipal & Danny Nguyen,
Risks and Benefits of Phase 1 Clinical Trial Participation, 21 CANCER CONTROL 193 (2014).
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drugs for sale in the United States have gone through a testing process to
ascertain that they are safe274 and effective.275
To reach this determination, the FDA “doesn't actually test drugs
itself” but rather relies on information provided by the Sponsor.276 Their goal
is to “ensure . . . that drugs, both brand-name and generic, work correctly and
that their health benefits outweigh their known risks.”277 The Sponsor cannot
begin drug testing in the United States until it receives preliminary clearance
from the FDA and receives approval for an Investigational New Drug
(“IND”). An IND obligates the Sponsor to put its study under the supervision
of an Institutional Review Board (“IRB”). 278 The Government itself often
uses the word “oversight” to describe the FDA’s role in the Clinical Trials
conducted by Sponsors.279 Recent legislation streamlining the FDA drug
review process could be used to support an argument that clinical drug trials

Farrah R. Raja, Evidentiary Standards for Drug Approvals in the 21st Century Cures Act:
A Continued Trend Towards Valuing Access over Safety for Pharmaceutical Drugs, 18 N.C.
J.L. & TECH. 409, 415 n.40 (2017) (“Reasonable safety is demonstrated when, based on
scientific evidence, the probable benefits from using the drug for its intended use outweigh
the probable risks associated with using the drug.” (citing Federal Food, Drug, and Cosmetic
Act, Pub. L. No. 75-17, 52 Stat. 1040 (1938))).
275
“Substantial evidence of effectiveness” is shown when qualified experts have reviewed
data from adequate and well-controlled studies and can conclude from the results of the data
that the drug will have its intended effect for its prescription and labeling uses. Id. at 414
(quoting Michelle Meadows, Promoting Safe and Effective Drugs for 100 Years, U.S. FOOD
& DRUG ADMIN. (Jan.–Feb. 2006), https://www.fda.gov/files/Promoting-Safe-andEffective-Drugs-for-100-Years-%28download%29.pdf [https://perma.cc/WMM5-267P]); see
also Development and Approval Process (Drugs), U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/default.htm [perma.cc/9ZRWELCE] (last updated Oct. 28, 2019) (explaining the FDA’s role as being one “[e]valuat[ing]
new drugs before they can be sold” to “not only prevent[] quackery, but also provide[] . . .
doctors and patients the information they need to use medicines wisely.”).
276
Development and Approval Process (Drugs), supra note 275.
277
Id.
278
See Recruiting Study Subjects: Guidance for Institutional Review Boards and Clinical
Investigators, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/RegulatoryInformation/
Guidances/ucm126428.htm [https://perma.cc/9MLT-HDVG] (last updated Sept. 5, 2018)
(“Advertising for recruitment into investigational drug, biologic or device studies should not
use terms such as ‘new treatment,’ ‘new medication’ or ‘new drug’ without explaining that
the test article is investigational. A phrase such as ‘receive new treatments’ leads study
subjects to believe they will be receiving newly improved products of proven worth.”)
279
In response to criticism from the Office of the Inspector General about gaps in the FDA’s
oversight, see OFF. OF INSPECTOR GEN., U.S. DEP’T OF HEALTH & HUM. SERVS., THE FOOD
AND DRUG ADMINISTRATION’S OVERSIGHT OF CLINICAL TRIALS (2007), https://oig.
hhs.gov/oei/reports/oei-01-06-00160.pdf [https://perma.cc/4JG4-RETK]. As of September
16, 2016, all clinical trials must be registered with the FDA. Submit Studies to
ClinicalTrials.gov PRS, CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/manage-recs/
submit-study [https://perma.cc/PX8P-SWPY] (last visited June 17, 2020).
274
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are activities sponsored by the federal government. 280 The FDA itself reports
annually on its role in bringing to market “novel” or “breakthrough drugs.” 281
Commonly, the first stage of drug trials involving human participants
is conducted with healthy people who are administered the products under
study and then monitored for adverse results. 282 Facilities running stage one
trials do not provide medical care, nor do they receive federal funding. They
maintain no relationship with treating physicians who are affiliated with
covered entities, but instead, they advertise directly to the public for
participants in the initial stages of drug testing.
There has been little litigation clarifying the status of stand-alone or
private clinical drug trial facilities relevant to the ADA. They have been
found subject to federal regulation regarding protection of human participants
in research and have been carefully described by the federal regulations
applying HIPAA privacy provisions. But whether or not any of these factors
or the “involvement” of the federal government makes a Clinical Drug Trial
an “activity” of the federal government is as yet unresolved.
In the absence of any legal resolution of the issue, sponsors may look
to a case from the Tenth Circuit rejecting a claim that a plasma donation
center, also a federally regulated entity, must be made accessible because it
was a place of public accommodation. 283 Instead, the Tenth Circuit held that
the plasma center was a “service establishment”284 though its purpose was
not to serve individuals who wanted to donate the plasma that the company
then sold to hospitals.285 Rather, its obligation was to be accessible to its
plasma customers, hospitals, and blood banks.286 In the same way, a Clinical
Trial Center may be seen as a “service establishment” to those using the
clinical data, not those providing it.

21st Century Cures Act, Pub. L. No. 114-255, 130 Stat. 1033 (2016) (codified as amended
in scattered sections of 21, 34, 38, and 42 U.S.C.).
281
Novel Drugs Summary 2015, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/Drugs/
DevelopmentApprovalProcess/DrugInnovation/ucm474696.htm [https://perma.cc/DTZ4-N9TK]
(last updated Jan. 12, 2016) (“[N]ovel drugs [] are among the more truly innovative products
that often help advance clinical care to another level.”) CDER issues annual reports on the
approval of novel drugs.
282
Some people make a living by participating in phase one trials. Cf. GPGP.NET – CLINICAL
TRIALS, MEDICAL TRIALS, UK, CANADA, USA, http://www.gpgp.net/ [https://perma.cc/
9E7U-8Q57] (last visited June 17, 2020) (providing a directory of trials seeking participants).
283
Levorsen v. Octapharma Plasma, Inc., 828 F.3d 1227, 1234–35 (10th Cir. 2016).
284
42 U.S.C. § 12181(7)(F).
285
Levorsen, 828 F.3d at 1234–35.
286
Id.
280
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2. Making reasonable accommodations under Title III of the ADA
Title III of the ADA requires that public entities take “reasonable”
measures to remove access barriers.287 The party refusing to make the
accommodation bears the burden of proving that it is not reasonable. 288 To
do so, it must show either that the accommodation “would result in an undue
financial or administrative burden” or would affect “a fundamental alteration
in the nature of the service.”289 Each of these categories has been subject to
significant legal interpretation.
3. Obligation of entities subject to Title III to eliminate barriers to
access to a research study
One of the likely objections to providing accommodations to make
research studies accessible is that doing so might invalidate research
results.290 Since neither Title II nor Title III impose an absolute duty on a
covered entity to provide a qualified plaintiff an accommodation for the
purposes of preventing discrimination, this objection will need to be faced
and rebutted.
42 U.S.C. § 12131(2).
28 C.F.R. § 35.150(a)(3) (2019). The regulations state that:
[I]n determining whether an action would result in an undue burden,
factors to be considered include—
(1) The nature and cost of the action needed under this part;
(2) The overall financial resources of the site or sites involved in the
action; the number of persons employed at the site; the effect on expenses
and resources; legitimate safety requirements that are necessary for safe
operation, including crime prevention measures; or the impact otherwise
of the action upon the operation of the site;
(3) The geographic separateness, and the administrative or fiscal
relationship of the site or sites in question to any parent corporation or entity;
(4) If applicable, the overall financial resources of any parent
corporation or entity; the overall size of the parent corporation or entity
with respect to the number of its employees; the number, type, and location
of its facilities; and
(5) If applicable, the type of operation or operations of any parent
corporation or entity, including the composition, structure, and functions
of the workforce of the parent corporation.
Id. § 36.104.
289
Id. § 35.150(a)(3); see also id. § 35.164 (relieving public entities from making an
accommodation that “would result in a fundamental alteration in the nature of a service,
program, or activity or in undue financial and administrative burdens.”); Prewitt v. U.S.
Postal Serv., 662 F.2d 292, 300 (5th Cir. 1981) (discussing that a program’s eligibility
requirement may discriminate against the disabled if the program's purposes may not be
achieved without the requirement).
290
See supra notes 180–89 and accompanying text.
287
288
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Title III requires that private entities offering public accommodations
must be proactive in their removal of barriers. Whether or not there is a
specific individual seeking access, their programs, equipment, and facilities
must be “designed, constructed, and altered in compliance with the
accessibility standards established by this part.” 291 Because of this obligation
of accessibility regardless of need, Courts have been receptive to arguments
by covered entities seeking to limit their obligations. In 2001, the Supreme
Court in PGA Tour v. Martin held that it would be illegal discrimination to
enforce a rule prohibiting players from travelling between holes by cart
against an individual with a qualified disability that made it unreasonably
difficult for him to walk the course.292 The Court’s caveat was that the PGA
could enforce the rule if they could demonstrate that doing so “would
fundamentally alter the nature of [the golf tournament].”293
Quoting Title III, the Court found that by not waiving the rule to allow
travel by cart the PGA was failing “to make reasonable modifications in
policies, practices, or procedures, when such modifications are necessary to
afford [access] to individuals with disabilities.” 294 Looking at another Title
III case four years later, the Court further explained that Title III “requires
only ‘reasonable modifications’ that would not fundamentally alter the nature
of the service provided.”295 An entity also may have eligibility requirements
that “impose legitimate safety requirements that are necessary for safe
operation.”296 However, those “safety requirements must be based on actual
risks and not on mere speculation, stereotypes or generalizations about people
with disabilities.”297 A private entity providing a public accommodation must
therefore present objective evidence that the inclusion of a person with a
disability in its activity would “fundamentally alter” its character. 298 In
Bragdon v. Abbott, Justice Ginsburg concurred with the majority opinion, but
wrote to note that in order to legally refuse to treat a patient with HIV in his
office a Dentist would have to prove that doing so “posed ‘a significant risk
to [his] health or safety of that [could not] be eliminated by a modification of
policies, practices, or procedures . . . .’”299

28 C.F.R. § 36.101(a) (2019).
PGA Tour, Inc. v. Martin, 532 U.S. 661, 688–89 (2001).
293
Id. at 682 (citing 42 U.S.C. § 12182(b)(2)(A)(ii)).
294
Id.
295
Tennessee v. Lane, 541 U.S. 509, 532 (2004).
296
28 C.F.R. § 36.301(b) (2019).
297
Id.
298
See Bragdon v. Abbott, 524 U.S. 624, 649 (1998) (“The existence, or nonexistence, of a
significant risk must be determined from the standpoint of the person who refuses the
treatment or accommodation, and the risk assessment must be based on medical or other
objective evidence.”).
299
Id. at 656.
291
292
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4. Provision of auxiliary aids and services
Next to ramps and elevators, the most familiar accommodations are
resources that provide assistance communicating. 300 These include but are
not limited to301 “Braille materials, qualified interpreters, assistive listening
devices, open or closed captioning and hearing aid compatible telephones.” 302
Both Title II303 and Title III mandate that covered entities must affirmatively
identify barriers to accessibility and take steps “as may be necessary” to
provide “auxiliary aids and services.”304 Dr. Rios argues that these kinds of
auxiliary aids “[k]eep the construct or essential elements consistent, while
eliminating difficulties associated with functional deficits.” 305 Describing
their work in designing accessible data collection devices, one research team
noted, “People with disabilities have often been excluded from participation
in clinical trials and other health-related research, either intentionally because
they did not meet the inclusion criteria, or unintentionally because they were
not able to travel to the research site or because no accommodations were
available for responding to paper-and-pencil test questionnaires.”306

See, e.g., Auxiliary Aids and Service, NAT’L DISABILITY NAVIGATOR RES.
COLLABORATIVE, https://nationaldisabilitynavigator.org/ndnrc-materials/disability-guide/
auxiliary-aids-and-services/ [https://perma.cc/HQ3B-8Q9B] (last visited July 17, 2020)
(describing devices or services that enable effective communication).
301
See 28 C.F.R. Pt. 35, app. A, at 560 (2019) (“The Department recognized in the preamble
to the 1991 title II regulation that the list of auxiliary aids was ‘not an all-inclusive or
exhaustive catalogue of possible or available auxiliary aids or services. It is not possible to
provide an exhaustive list, and an attempt to do so would omit the new devices that will
become available with emerging technology.’ The Department continues to endorse that
view; thus, the inclusion of a list of examples of possible auxiliary aids in the definition of
“auxiliary aids” should not be read as a mandate for a title II entity to offer every
possible auxiliary aid listed in the definition in every situation.” (citation omitted)).
302
See id. § 35.160(b)(2) (requiring public entities to provide “the type of auxiliary aid and
service necessary to ensure effective communication.”); id. § 36.303(b) (defining the types
of auxiliary aids and services under Title III).
303
See 42 U.S.C. § 12182 (prohibiting discrimination based on disability and including that
“failure to take such steps as may be necessary” to ensure no one is excluded based on the
“absence of auxiliary aids and services” unless such steps would result in “undue burden” is
prohibited).
304
Id.
305
See Rios et al., supra note 37, at 2139 (providing, as an example, allowing a person with
“limited hand control” to dictate responses to a survey rather than write them).
306
Mark Harniss, Dagmar Amtmann, Debbie Cook & Kurt Johnson, Considerations for
Developing Interfaces for Collecting Patient-Reported Outcomes that Allow the Inclusion Of
Individuals with Disabilities, 45 MED. CARE S48, S48–54 (2014).
300
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Since many research studies both recruit on the web307 and rely on
participants having access to their websites, they are likely to be already
under statutory obligation to make their websites accessible. 308 Websites
themselves have been found to be places of “public accommodation” under
Title III.309
5. Is exclusion of people with disabilities a necessary action which
would otherwise fundamentally alter the character of the research?
Anticipating the objections that researchers would raise in the face of
demands that they include people with disabilities, Rios and her team
considered objections based on the risk of harm to the scientific validity of
the study.310 For this concern to justify exclusion, however, researchers
would have to show that the modifications required for exclusion would
fundamentally alter the activity or create genuine safety risks. One
accommodation might be to allow a service animal to access many places
where a pet could not go, but without allowing the animal to access an
operating room or even an x-ray suite where it might harm itself or others. 311
Arguments against including people with disabilities take many forms
but one of the most common is that their inclusion would impair the
generalizability of the collected data. Moore and her team have suggested that
using the same statistical methods that allow researchers to break out results
307

The National Institute of Health provides a website as a resource for patients and families,
as do many universities. See CLINICALTRIALS.GOV, https://clinicaltrials.gov/ [https://perma.cc/
4PPM-9LGK] (last visited June 17, 2020) (providing NIH resources on research studies and
clinical trials); About This Site, INST. TRANSLATIONAL HEALTH SCI., https://www.iths.org/
participate/about/about-this-site/ [https://perma.cc/AAK7-5BNB] (last visited June 17,
2020) (showing an example of a university webpage with resources for patients regarding
research participation).
308
See generally, Laura L. Carlson, HIGHER ED ACCESSIBILITY LAWSUITS, COMPLAINTS, AND
SETTLEMENTS, https://www.d.umn.edu/~lcarlson/atteam/lawsuits.html [https://perma.cc/AAK75BNB] (last visited June 17, 2020) (presenting an ongoing source of website accessibility
actions in higher education).
309
See Terese L. Arenth, ADA Web Site Accessibility Claims on the Rise: Practical Strategies
for Defense, 23 J. INTERNET L. 1, 13 (2019) (“The body of case law that has developed around
ADA Web site compliance has been almost universally pro-plaintiff.”); Robles v. Domino’s
Pizza, LLC, 913 F.3d 898, 905–07 (2019), cert. denied, 140 S. Ct. 122 (2019) (reversing
district court’s grant of a web site operator’s motion to dismiss on grounds that the ADA
applied to the website and that the operator received fair notice of that fact).
310
Rios et al., supra note 37, at 2137.
311
28 C.F.R. § 36.302(a) (2019) (“A public accommodation shall make reasonable
modifications in policies, practices, or procedures, when the modifications are necessary to
afford goods, services, facilities, privileges, advantages, or accommodations to individuals
with disabilities, unless the public accommodation can demonstrate that making the
modifications would fundamentally alter the nature of the goods, services, facilities,
privileges, advantages, or accommodations.”).

Vol. 6:3]

Lifting the Barriers

553

from specific populations would show whether or not there were significant
differences that could be attributed to the accommodations. 312
Some researchers justify exclusion of people with an intellectual
disability by claiming that the accommodations needed to provide informed
consent would, themselves, fundamentally alter the nature of the study. 313
Given the mandate that all medical equipment must be accessible, it
is difficult to imagine a court crediting a healthcare provider’s argument for
exclusion based on the need to obtain or alter existing equipment for the
research study.314 However, a study that takes place at a clinical trial center
that does not provide healthcare may gain traction with this argument.315
In PGA Tour v. Martin, the Supreme Court made clear that a change in
equipment does not justify discrimination. Rather, the difference must be one
that would be a “fundamental alteration” of the character of the activity.316

See Rita Hamilton, Simon Driver, Shayan Noorani, Librada Callender, Monica Bennett
& Kimberley Monden, Utilization and Access To Healthcare Services Among CommunityDwelling People Living With Spinal Cord Injury, 40 J. SPINAL CORD MED. 321, 327 (2017)
(stating that when building new and retro-fitting existing medical facilities it is critical to
consider the principle of “‘universal design’, which ensures that accessibility to buildings
and public spaces is fully accessible for people with disabilities.”); see also Universal
Design, CTR. FOR AN ACCESSIBLE SOC’Y, http://www.accessiblesociety.org/topics/
universaldesign/ [https://perma.cc/34GN-KM5C] (last visited June 17, 2020) (“Universal
design is an approach to design that works to ensure products and buildings can be used by
virtually everyone, regardless of their level of ability or disability.”).
313
See Teresa Iacono & Vanessa Murray, Issues of Informed Consent in Conducting Medical
Research Involving People with Intellectual Disability, 16 J. APPLIED RES. INTELL.
DISABILITIES 41, 49 (2003) (reviewing the challenges of obtaining informed consent in a
study including people with intellectual disabilities but concluding that modifications could
be made to provide sufficient protection; “[i]n universities, with developed research cultures,
there is an implicit understanding of a need to protect potentially vulnerable participant
groups, while ensuring that demands placed on researchers are not so restrictive as to
preclude valuable research.”).
314
Rios et al., supra note 37, at 2141 (“Ideally, if universal design, accommodations, or both
are provided with disabilities should be able to participate in some or all research-related
activities.”).
315
A study being advertised by Duke University’s Preston Robert Tisch Brain Tumor Center,
a private entity, lists exclusions which provide good illustrations of an accommodation
argument. One such exclusion involves the ability of patients to use the imaging equipment
used in the study. It excludes “[p]atients who cannot undergo MRI or SPECT due to obesity
or to having certain metal in their bodies (specifically pacemakers, infusion pumps, metal
aneurysm clips, metal prostheses, joints, rods, or plates).” History of Changes for Study;
NCT01009866, CLINICALTRIALS.GOV (March 18, 2015), https://clinicaltrials.gov/ct2/his
tory/NCT01009866?V_1=View [https://perma.cc/6RK6-JD5W].
316
PGA Tour, Inc. v. Martin, 532 U.S. 661, 683 (2001) (“[T]he use of carts is not
itself inconsistent with the fundamental character of the game of golf. From early on, the
essence of the game has been shotmaking—using clubs to cause a ball to progress from the
teeing ground to a hole some distance away with as few strokes as possible.”).
312
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However, should that exclusion disparately affect people with
disabilities, then the sponsor would have to provide a safety justification that
withstands the factual scrutiny of the court. 317 This could violate
requirements of the ADA mandating accessible medical equipment. 318
Moreover, if the lack of accessibility was a feature of the facility or the
medical equipment, the feature would have to be modified. The exclusion of
“obesity” raises other issues. While obesity itself may not be a disabling
condition, if the obesity is due to a qualified condition exclusion of an obese
participant too may be illegal. In general, it seems likely that this study would
exclude an individual who could not access MRI equipment without
modification, regardless of reason, which is illegal.
Another reason why study designs that exclude people living with
disabilities may violate the ADA comes from the Supreme Court’s decision
in Lane.319 There, the Court found that the ADA prohibited preemptive,
categorical exclusions. Instead, it required that covered entities make
decisions on accommodations based on the facts of individual situations.320
Some of the exclusions of people living with disabilities in study
protocols are shockingly direct. For example, a study posted on the NIH’s
Clinical Trials website explicitly states that a “[m]ajor medical illnesses or
psychiatric impairments that, in the investigator's opinion, will prevent
administration or completion of protocol therapy.” 321 This kind of exclusion
is similar to the preemptive restrictions criticized in Lane. Without specific
proof that an individual had demonstrated behavior inconsistent with
inclusion, such sweeping prohibitions are unlikely to be found appropriate. 322

See Tennessee v. Lane, 541 U.S. 509, 533 (2004) (“[O]rdinary considerations of cost and
convenience alone cannot justify a State’s failure to provide individuals with a meaningful
right of access to the courts.”).
318
Pendo, supra note 209, at 33.
319
Lane, 541 U.S. at 509.
320
Id. at 531–32.
321
Gary Archer, DC Migration Study for Newly-Diagnosed GBM (ELEVATE),
CLINICALTRIALS.GOV (Nov. 7, 2017), https://clinicaltrials.gov/ct2/show/study/NCT02366
728? term=NCT02366728&rank=1&show_desc=Y#desc [https://perma.cc/W2DN-FP6T].
322
This assumes that the excluded plaintiff does indeed have a “qualified disability” rather
than just a pattern of noncompliant behavior. See generally Carolyn Mason, The Social
Maladjustment Exclusion: Leaving a Category of Students Behind and the Problem with
State and Judicial Interpretation of Congressional Intent, 19 U.D.C. L. REV. 91 (2016)
(reviewing cases where courts distinguish between mental disability and social
maladjustment).
317
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G. Exclusion from Research Conducted by Entities Which Provide Health
Care to the Public
Research studies conducted by entities which provide healthcare to
the public are subject to both Title II and Title III of the
ADA.323 Section 1557 of the Affordable Care Act has added another layer of
protection by prohibiting discrimination against patients on the basis of
disability status.324 It also made clear that its protections extended to all
entities who receive any federal funding, even if the discrimination takes
place in a division that does not provide healthcare.325 This is particularly
relevant to research because many academic medical centers have created
separate entities to partner with private sponsors.326

For an overview of how Title II, Title III, and the Rehabilitation Act of 1973 overlap in
prohibiting discrimination associated with receiving healthcare, see ACCESS TO MEDICAL
CARE, supra note 254, at 1 (“Titles II and III of the ADA and Section 504 require that medical
care providers provide individuals with disabilities: full and equal access to their health care
services and facilities; and reasonable modifications to policies, practices, and procedures
when necessary to make health care services fully available to individuals with disabilities,
unless the modifications would fundamentally alter the nature of the services (i.e. alter the
essential nature of the services).”).
324
42 U.S.C. § 18116.
325
See Rumble v. Fairview Health Servs., No. 14-CV-2037, 2015 WL 1197415, at *10 (D.
Minn. Mar. 16, 2015) (citations omitted) (“[A]s long as part of an organization or entity
receives federal funding or subsidies of some sort, the entire organization is subject to the
anti-discrimination requirements of Section 1557. A potential plaintiff need not seek medical
care specifically from the part of the organization that receives federal funding. Rather, the
organization is only required to have a health program or activity that receives federal
financial assistance.”); Allison M. Tinsey, Comment, Regulating Relief: Private Right of
Action Jurisprudence in Healthcare Discrimination Cases, 20 RICH. PUB. INT. L. REV. 305
(2017) (reviewing extension of private rights of action provided by Section 1557).
326
See NAT’L COUNC. ON DISABILITY, MONITORING AND ENFORCING THE AFFORDABLE
CARE ACT (ACA) FOR PEOPLE WITH DISABILITIES (2016) (“If one part of an entity that is
principally engaged in providing or administering health services or health insurance
coverage receives federal funding, the entire entity is forbidden to discriminate.”); see also
United States v. Baylor Univ. Med. Ctr., 736 F.2d 1039, 1049 (5th Cir. 1984) (finding that a
private hospital receiving Medicare and Medicaid payments is subject to Section 504);
Rumble, 2015 WL 1197415, at *12 (citation omitted) (quoting 42 U.S.C. § 18116)
(“According to the ACA, entities that are subject to the anti-discrimination provisions in
Section 1557 include ‘any health program or activity, any part of which is receiving Federal
financial assistance, including credits, subsidies, or contracts of insurance,’ or ‘any program
or activity that is administered by an Executive Agency or any entity established under this
title (or amendments).’ Thus, as long as part of an organization or entity receives federal
funding or subsidies of some sort, the entire organization is subject to the anti-discrimination
requirements of Section 1557.”).
323
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H. Is Exclusion from a Clinical Trial Exclusion from Healthcare?
The focus of current clinical drug trials to find an effective treatment
for the novel coronavirus are taking place in hospitals with participants who
are extremely sick. 327 It is well established that entities providing healthcare
to the public cannot discriminate based on disability. 328 So if the only
healthcare available involves participating in a clinical trial—is exclusion
from a clinical trial exclusion from healthcare? While this point is not
essential to making a prima facie claim of disability discrimination, since a
clinical trial is an activity of a covered entity, it would strengthen the
plaintiff’s position. There are strong arguments in favor of making such a
claim. The increasing importance of clinical trials as a component of the U.S.
healthcare system and the persistent advertising by sponsors of clinical trials
have created a public climate329 in which access to clinical trials is perceived
as a standard part of receiving medical care. 330
Writing about the vulnerability of patients seeking access to Drug
Trials, bioethicist Jerry Menikoff noted that in a situation where “the existing
treatments for the patient's illness are unsatisfactory, and participation in the
study offers some possibly more satisfactory treatment . . . that study—with
its offer of access to some new treatment by participating in the study—might
well be the best therapeutic option.” 331 This is especially true when the only
effective treatment involves enrollment in a clinical trial. Without other
See, e.g., Efficacy of Convalescent Plasma Therapy in Severely Sick Covid-19 Patients,
CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT04346446 [https://perma.cc/GBR9B8LV] (last updated June 12, 2020) (detailing one clinical drug trial for COVID-19
treatments and the health of the participants); Roni Caryn Rabin, Steroids Can Be Lifesaving
for Covid-19 Patients, Scientists Report, N.Y. TIMES (Nov. 2, 2020), https://www.nytimes.com/
2020/09/02/health/coronavirus-steroids.html [https://perma.cc/N9SY-9NXJ] (describing the
results of studies treating severely ill patients with steroids).
328
Health Care and the Americans with Disabilities Act, ADA NAT’L NETWORK,
https://adata.org/factsheet/health-care-and-ada [https://perma.cc/RDP2-SEB5] (instructing
“[h]ealth care organizations that provide service to the public” to fulfil their legal obligation
by “provid[ing] full and equal access for people with disabilities . . . . Reasonable
modifications of policies, practices, and procedures . . . . Effective Communication . . . . [and]
Accessible Facilities”).
329
An example of this comes from the publicity surrounding former President Jimmy
Carter’s announcement on December 6, 2015, to his Sunday School class that he was now
free of the brain cancer with which he had been diagnosed six months before. Andrew Weil,
What Cured Jimmy Carter’s Cancer?, DR. WEIL BLOG (Dec. 11, 2015), https://
www.drweil.com/health-wellness/body-mind-spirit/cancer/what-cured-jimmy-carters-cancer
[https://perma.cc/6JDT-S429].
330
What Are Clinical Trials and Studies?, NAT’L INST. ON AGING, https://www.nia.nih.gov/
health/what-are-clinical-trials-and-studies [https://perma.cc/8S79-CBRK] (last reviewed
Apr. 9, 2020).
331
Jerry Menikoff, The Vulnerability of the Very Sick, 37 J.L. MED. & ETHICS 51, 55 (2009).
327
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options for getting well, it is hard to argue that participants made a choice
between treatment and research.
Until recently, it was generally understood that decisions related to
medical care were not covered by the ADA. This was based on a series of
cases involving third party attempts to interfere with parents’ decisions to
withhold life-sustaining care from critically ill infants.332 However, as Sam
Bagenstos explains in a recent piece in the Yale Law Journal Forum, these
cases may not apply to the current situation. He writes that “[t]he refusal to
provide coronavirus treatment to patients with pre-existing disabilities” who,
either directly or through surrogate decision makers, assert that they want to
be treated, is the exact opposite of preventing family members from making
decisions about when to withdraw treatment. 333 Citing the Supreme Court in
Pennsylvania Department of Corrections v. Yeskey,334 he argues that whether
or not Congress anticipated the ADA being applied to rationing of care in
pandemics, “the fact that a statute can be ‘applied in situations not expressly
anticipated by Congress does not demonstrate ambiguity.’”335
I. Is This a Claim that People Living with Disabilities Have a Right to
Participate in Research Studies?
Prohibiting disability-based discrimination is not the same as
claiming a right to participate in any particular clinical trial just as prohibiting
sex discrimination is not the same as claiming a right to any particular job.
Readers of this article are likely to ask whether seeking access to a clinical
trial is a variation of the arguments already rejected in Abigail Alliance for
Better Access to Developmental Drugs v. von Eschenbach336 that there is a
See LAURA ROTHSTEIN, DISABILITIES AND THE LAW § 10:2 (4th ed.), Westlaw (database
updated October 2020) (explaining the history of the case law relating to medical treatment of
infants with disabilities); Schiavo ex rel. Schindler v. Schiavo, 403 F.3d 1289, 1294 (11th Cir.
2005) (observing that the Rehabilitation Act, like the ADA, was never intended to apply to
decisions involving medical treatment); Fitzgerald v. Corr. Corp. of Am., 403 F.3d 1134, 1144
(10th Cir. 2005) (finding that inmate's claims under the Rehabilitation Act and ADA were properly
dismissed for failure to state a claim because they were based on medical treatment decisions).
333
Bagenstos, supra note 20, at 24.
334
524 U.S. 206 (1988).
335
Bagenstos, supra note 20, at 23 (quoting Yeskey, 524 U.S. at 212).
336
See Abigail All. for Better Access to Developmental Drugs v. von Eschenbach, 495 F.3d
695, 723 (D.C. Cir. 2007), cert. denied, 128 S. Ct. 1069 (2008) (drawing an analogy to the
doctor/patient relationship and noting that there was no obligation under the common law of
the United States for any individual physician to provide treatment to any individual patient);
Jerry Menikoff, Beyond Abigail Alliance: The Reality Behind the Right to Get Experimental
Drugs, 56 KAN. L. REV. 1045, 1056 (2008) (noting that even if the Court had found a
constitutional right, “[t]he FDA would not have been ordered to take any active measures to
make sure the plaintiffs could indeed obtain these drugs. Nor would a victory have provided
332
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Constitutional right to access possibly life-saving drugs before they are
approved for sale by the FDA. It is not. Rather the claim here is the right to
be free of discrimination based on disability. The distinction is most clear
when considering Title III of the ADA which applies to private entities
offering public accommodations. All of these private entities are free to
refuse service on any ground other than illegal discrimination. The same
applies to a public entity, like a university or one of the service academies,
which are free to establish any admission criteria they want, so long as they
are not based on illegal discrimination. Nor is the issue of lack of access
solved by the federal and state “right to try” statutes passed in response to the
Supreme Court’s denial of certiorari in Abigail Alliance. These statutes
merely streamlined existing “compassionate use” policies337 that removed
legal impediments preventing the FDA from granting individual waivers for
access to unapproved drugs. 338 They did not impose any obligations on the
entities, public or private, who were conducting the drug trial. So, while there
is no constitutional right or statutory entitlement to participate in a clinical
trial, there can be no exclusion based on illegal discrimination.
CONCLUSIONS
This article is the first to move the exclusion of people living with
disabilities from research studies from the category of moral or ethical wrong
to that of actionable legal wrong. It does so in two stages. First, this article
marshals the available evidence for exclusion of people living with
disabilities from research studies, details the harm of exclusion, and addresses
the excuses for exclusion. Second, having defined the problem, it then
identifies legal remedies, primarily under the Americans with Disabilities
Act, that are available to individuals who experience disability-based
discrimination across the spectrum of research studies, whether funded or
regulated by the federal government or conducted by a private entity. The
work here is similar to that which has been done to address the exclusion of
other populations historically both mistreated by and excluded from research
studies, including women, African Americans, prisoners, and the elderly.
the plaintiffs with any right to order drug companies, or any other private individuals or
organizations, to provide the drugs.”).
337
See Expanded Access, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/newsevents/public-health-focus/expanded-access [https://perma.cc/6QFX-VRPS] (last updated
Apr. 27, 2020) (providing an overview of compassionate use).
338
In addition to the regular “right to try” statutes, Congress has given the FDA considerable
power to expand access to otherwise restricted drugs and biologics during an emergency.
See, e.g., Joyner, supra note 17 (“This expanded access program will provide access to
investigational convalescent plasma for patients in acute care facilities infected with SARSCoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare
provider to be at high risk of progression to severe or life-threatening disease.”).
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However, it is only recently that the U.S. government has recognized people
living with disabilities as a population experiencing disparately worse health
outcomes and linked these outcomes to exclusion from research. In so doing,
it is several years behind governments in Europe and the U.K. which have
already passed laws legislating inclusion.
The need to right a historic wrong, the exclusion of people living with
disabilities from research studies, is particularly acute as the United States is
facing COVID-19—a challenge demanding extraordinary resources of every
kind and testing our commitment to care equally for all our citizens. As drug
therapy for COVID-19 is experimental and many drugs are only available by
enrolling in research studies, there is considerable urgency to make sure that
whatever their care setting—public or private, nursing home or out-patient—
people living with disabilities have equal access to care. In concluding that the
ADA mandates inclusion in research studies, I am well aware that despite
widespread public, bipartisan support, the ADA’s history from passage to today
has been one of vigorous litigation seeking to limit its scope. To argue that people
living with disabilities who are excluded from a research study could invoke the
ADA’s protection is not to underestimate the complexity of this task or to be
overly optimistic about the likelihood of successfully achieving accessibility to
every kind of research study. Instead, this article intends to frame exclusion from
research studies as the kind of discrimination that is protected by existing antidiscrimination laws and to identify a framework for matching the type of
research and the kind of disabling condition to the relevant provisions of the
ADA. Now is the time to stop looking at inclusion of any underrepresented
population as an issue of ethics or even social justice but rather as a legal
entitlement flowing from anti-discrimination laws which, so far, have never been
used to demand access to research studies.

